Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Merlintrader Research Library: Dated Stock Research Reports in PDF
The full research behind our stock hubs, collected as dated PDF reports. Each report is a snapshot of the research on the date printed on its cover and is not updated after that date. For the current situation of each company, follow its stock hub.
1 · AccessUnlock the library by watching a short ad or with a contribution.
2 · DownloadEach access includes up to 2 reports, valid for 12 hours.
3 · ReadEvery report carries its date, its sources and its disclaimer. Redistribution is prohibited.
Library access
Unlock the reports
Watch a short ad or support Merlintrader with a contribution. You decide, we don’t recommend.
The library is open. Up to 2 downloads are included with this access.
Reports in the library
$OCGNResearch as of October 26, 2026PDF · 28 pages
Ocugen: the December 22 share vote, the cash-settled notes and three registrational trials
The special meeting on 250 million new shares, the $130 million convertible notes that must be settled in cash until it passes, cash and the going-concern conclusion, the OCU400, OCU410 and OCU410ST programmes, ownership, short interest, legal matters, the catalyst map, sources and FAQ.
$POETResearch as of October 26, 2026PDF · 22 pages
POET Technologies: the Lumilens order, the Malaysian ramp and the path to revenue
Three scenarios, the $50 million Lumilens order and its customer warrant, the other orders and the Celestial AI cancellation, quarterly results, cash and monthly burn, manufacturing capacity in Penang, debt and strategic assets, the 2026 financings, warrants and awards, ownership, short interest, legal matters, sources and FAQ.
$IOVAResearch as of October 28, 2026PDF · 32 pages
Iovance Biotherapeutics: Amtagvi, the raised 2026 revenue guidance and the clinical pipeline
Amtagvi and Proleukin commercial ramp, the September 29 revenue guidance raise to $410–420 million, the authorized treatment center network, TILVANCE-301 and the lung, sarcoma and endometrial programs, cash, burn and the at-the-market program, ownership, risks, sources and FAQ. A snapshot dated before the October 29 lung-cancer update; the current situation is on the hub.
$ALTResearch as of October 26, 2026PDF · 40 pages
Altimmune: Pemvidutide, MASH trials and the liver-disease pipeline
A dated review of pemvidutide across MASH, alcohol use disorder and alcohol-associated liver disease, covering IMPACT, PERFORMA, RECLAIM and RESTORE, the balance sheet, financing and dilution, clinical catalysts and development risks.
$AVXLResearch as of October 28, 2026PDF · 31 pages
Anavex: Blarcamesine, the Rett program and the regulatory record
A dated review of blarcamesine in Alzheimer’s disease, Rett syndrome and Fragile X, the European application withdrawal, U.S. development plans, cash and financing, equity dilution, governance, legal proceedings and clinical risks.
$BBAIResearch as of October 28, 2026PDF · 21 pages
BigBear.ai: Secure AI, Ask Sage, contracts and cash conversion
A dated review of BigBear.ai’s government and commercial AI business, Ask Sage, customers, contract funding and backlog, margins and cash flow, liquidity, debt and dilution, governance and operating risks.
$BEResearch as of October 28, 2026PDF · 20 pages
Bloom Energy: AI power, fuel-cell deployments and cash conversion
A dated review of Bloom Energy’s fuel-cell business, financial results, cash and working capital, debt and dilution, Oracle and Brookfield programs, Army conditional projects, market context and operating risks.
$CAPRResearch as of October 26, 2026PDF · 60 pages
Capricor Therapeutics: Deramiocel, HOPE-3 and the FDA review
A dated review of deramiocel’s regulatory sequence, HOPE-3 and extension evidence, financial position and dilution, commercial-partner and legal risks, ownership, and the November FDA target and lease contingency.
$CRDFResearch as of October 29, 2026PDF · 26 pages
Cardiff Oncology: Onvansertib, Phase 3 funding and the Nerviano agreement
A dated review of onvansertib and CRDF-004, the registrational plan, the Nerviano settlement and license obligations, financial resources, going concern, equity dilution, governance and clinical-development risks.
$DRTSResearch as of October 26, 2026PDF · 23 pages
Alpha Tau Medical: Alpha DaRT, REGAIN, ReSTART and the funding test
A dated review of Alpha DaRT clinical programs and early evidence, ReSTART, REGAIN and IMPACT, the Tolmar relationship, cash and borrowing, shares and warrants, ownership and clinical-development risks.
$GERNResearch as of October 27, 2026PDF · 45 pages
Geron: RYTELO sales, gross-to-net deductions and financing
A dated October 27 review of RYTELO sales, guidance, deductions, cash, debt and royalties, dilution, litigation and the then-current development program. This historical report precedes the October 28 IMpactMF discontinuation; see the live hub for that update.
$HELPResearch as of October 28, 2026PDF · 23 pages
Helus Pharma: APPROACH, HLP003 and HLP004 development
A dated review of the adjunctive depression program, APPROACH and the pivotal evidence test, HLP004 in anxiety, treatment-delivery considerations, finances, equity claims, governance and clinical-development risks.
$HTZResearch as of October 29, 2026PDF · 24 pages
Hertz: Rental recovery, fleet financing, debt and Oro Mobility
A dated review of rental and fleet economics, results, cash and corporate liquidity, vehicle and non-vehicle debt, ABS and exchangeable financing, Oro Mobility, dilution, litigation and operating risks.
$HYLNResearch as of October 28, 2026PDF · 23 pages
Hyliion: KARNO, Navy research and the path to commercial power
Dated research on KARNO technology, validation, Navy programs, data-center demand, manufacturing, financial reserves, dilution and execution risks.
$IBRXResearch as of October 27, 2026PDF · 50 pages
ImmunityBio: ANKTIVA, QUILT data and the capital structure
Complete dated research on ANKTIVA, approved uses, clinical programs, commercial execution, cash, dilution, litigation, governance and regulatory risks.
$ICUResearch as of October 28, 2026PDF · 24 pages
SeaStar Medical: QUELIMMUNE, adult AKI and the funding bridge
Dated research on pediatric QUELIMMUNE, hospital codes and sales, the adult NEUTRALIZE-AKI trial, clinical evidence, cash, financing, warrants, ownership and risks.
$INOResearch as of October 26, 2026PDF · 54 pages
INOVIO: INO-3107 review, RRP evidence and financing
Complete dated research on INO-3107 and accelerated approval, RRP clinical evidence, competition, cash, warrants and dilution, governance, litigation and the wider pipeline.
$KODResearch as of October 27, 2026PDF · 23 pages
Kodiak Sciences: Zenkuda, DAYBREAK, PEAK and the funding path
Dated research on the Zenkuda recovery, GLOW and DAYBREAK, KSI-101 and MESI, clinical scenarios, finances, capital structure, management, competition and risks.
$KOPNResearch as of October 28, 2026PDF · 22 pages
Kopin: Microdisplays, Neural I/o and usable cash
Dated research on quarterly results, product margins, cash and collateral, financing and dilution, OLED and MicroLED programs, Neural I/o, Theon, ownership and risks.
$KPTIResearch as of October 28, 2026PDF · 25 pages
Karyopharm: Selinexor, creditor deadlines and the capital structure
Dated research on XPOVIO, SENTRY and the myelofibrosis regulatory path, endometrial and myeloma programs, financial obligations, dilution, management, competition and risks.
$LACResearch as of October 28, 2026PDF · 19 pages
Lithium Americas: Thacker Pass construction, funding and dilution
Dated research on Thacker Pass, construction milestones, cash and burn, DOE financing, Yorkville conversion, share dilution, partners, ownership and execution risks.
$MDAResearch as of October 28, 2026PDF · 22 pages
MDA Space: CHORUS, backlog, cash conversion and acquisitions
Dated research on the business and currencies, CHORUS and satellite programs, quarterly results, backlog, cash and working capital, debt, acquisitions, ownership and risks.
$NRXPResearch as of October 26, 2026PDF · 42 pages
NRx Pharmaceuticals: Ketamine review, clinics, funding and dilution
Complete dated research on the generic and branded ketamine pathways, FDA correspondence, cash and burn, capital structure, HOPE clinics, DARPA, governance and risks.
$NVAXResearch as of October 26, 2026PDF · 24 pages
Novavax: Nuvaxovid, Sanofi economics and the royalty transition
The October 26 research snapshot examines seasonal approvals and clinical evidence, Sanofi and other partnerships, revenue, cash, debt and Gavi obligations, dilution, ownership and operating risks.
$OCULResearch as of October 26, 2026PDF · 20 pages
Ocular Therapeutix: AXPAXLI filing plans, repeat dosing and funding
The October 26 report examines SOL-1 evidence and its comparator, the proposed NDA package, SOL-R, retina competition, DEXTENZA, cash runway, Barings debt, dilution and ownership.
$OMERResearch as of October 26, 2026PDF · 45 pages
Omeros: YARTEMLEA launch, European refusal and post-repurchase liquidity
The October 26 research snapshot examines TA-TMA evidence, the U.S. launch and reimbursement, the European refusal, competition, finances, convertible notes, the Novo transaction, pipeline and risks.
$ONDSResearch as of October 26, 2026PDF · 22 pages
Ondas: defense orders, acquisition integration and cash conversion
The October 26 research snapshot covers the enlarged defense platform, revenue and margins, backlog, cash and working capital, DZYNE, Cyberhawk, GATE and Bron, share commitments, warrants and ownership.
$OTLKResearch as of October 26, 2026PDF · 26 pages
Outlook Therapeutics: LYTENAVA launch, cash runway and capital risks
The October 26 research snapshot examines the FDA and clinical history, U.S. launch and pricing, reimbursement, cash, Atlas obligations, European commercialization, dilution, ownership, listing and legal risks.
$PLUGResearch as of October 28, 2026PDF · 22 pages
Plug Power: hydrogen economics, cash conversion and funding
The October 28 research snapshot examines margins and fuel losses, Q2 statements and preliminary Q3 estimates, cash, asset monetization, debt, equity facilities, warrants, projects, working capital and ownership.
$RKLBResearch as of October 29, 2026PDF · 26 pages
Rocket Lab: Electron commitments, Neutron and the proposed Iridium deal
The October 29 research snapshot covers launch and Space Systems execution, Synspective, Neutron development, results, revenue recognition, backlog, cash, acquisitions, Iridium, financing, dilution and governance.
$RZLVResearch as of October 28, 2026PDF · 26 pages
Rezolve AI: agentic commerce, Investor Day and financing
The October 28 research snapshot examines the enlarged commerce platform, H1 results, guidance and ARR, cash and cost plans, Monroe debt, share issuance, warrants, partners, ownership and risks.
$SMMTResearch as of October 28, 2026PDF · 21 pages
Summit Therapeutics: ivonescimab evidence, FDA review and financing
The October 28 research snapshot covers Akeso license economics, the FDA application, original and later HARMONi analyses, global trials, cash, the AstraZeneca investment, dilution, governance and collaborations.
$SNDLResearch as of October 29, 2026PDF · 23 pages
SNDL: retail cash, Parallel and capital returns
The October 29 research snapshot covers Canadian operations, Q3 cash and leases, SunStream investments, Parallel, capital allocation, regulatory risks and dated sources.
$SPCEResearch as of October 28, 2026PDF · 20 pages
Virgin Galactic: flight tests, the new fleet and financing
The October 28 research snapshot examines Apeiron's flight-test transition, the commercial timetable, customer bookings, liquidity, debt, warrants, share dilution and primary sources.
$SRPTResearch as of October 29, 2026PDF · 26 pages
Sarepta: ELEVIDYS, PMO review and the RNA pipeline
The October 29 research snapshot examines marketed Duchenne therapies, liver safety, ESSENCE and FDA conversion review, early RNA programs, commercial results, debt, licensed economics and litigation.
$VERAResearch as of October 27, 2026PDF · 21 pages
Vera Therapeutics: TRUTAKNA, ORIGIN 3 and launch economics
The October 27 research snapshot covers accelerated approval, final randomized ORIGIN 3 efficacy, exploratory PIONEER observations, launch execution, Oxford financing, licensed economics and dilution.
$XERSResearch as of October 29, 2026PDF · 23 pages
Xeris Biopharma: Recorlev growth, XP-8121 and cash generation
The October 29 research snapshot covers marketed products, Recorlev safety and patent disputes, XP-8121's pivotal plan, quarterly economics, cash generation, debt settlement, secured borrowing and dilution.
$SLSResearch as of October 29, 2026PDF · 26 pages
SELLAS Life Sciences: REGAL final analysis, SLS009 and the funding behind the readouts
The full research covers GPS and the REGAL survival analysis, the SLS009 clinical and preclinical evidence, cash and operating burn, warrant-driven dilution, licensing obligations, institutional ownership, short positioning, scenarios, the dated catalyst framework, risks, primary sources and FAQ. Research and regular-session market reference: October 29, 2026.
$MDAIResearch as of October 29, 2026PDF · 22 pages
Spectral AI: DeepView authorization, commercial launch and the funding bridge
The full research covers DeepView and the FDA order, clinical evidence and label expansion, commercialization, BARDA funding, NTAP reimbursement, cash and operating burn, Avenue debt, share dilution, institutional and insider ownership, scenarios, dated catalysts, risks, sources and FAQ. Research and regular-session market reference: October 29, 2026.
$AMRNResearch as of October 29, 2026PDF · 19 pages
Amarin: VASCEPA cash conversion, partner economics and EMT2 evidence
The full research covers VASCEPA and VAZKEPA, third-quarter earnings, liquidity and working-capital quality, contractual obligations, REDUCE-IT and EMT2 evidence, international partners, the Hikma settlement and remaining legal matters, ADSs and share dilution, ownership, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.
$ARDXResearch as of October 29, 2026PDF · 26 pages
Ardelyx: IBSRELA growth, XPHOZAH access and the capital behind execution
The full research covers IBSRELA and XPHOZAH, patient access and reimbursement, clinical evidence, ACCEL and RDX10531, revenue and operating cash flow, secured debt and covenants, share dilution, ownership, filed litigation, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.
$MBOTResearch as of October 29, 2026PDF · 19 pages
Microbot Medical: LIBERTY orders, European timing and the economics of launch
The full research covers LIBERTY and its cleared use, clinical evidence, repeat orders, European timing, manufacturing, revenue, cash and historical burn, share dilution, ownership, filed litigation, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.
$MNKDResearch as of October 29, 2026PDF · 24 pages
MannKind: ReadyFlow launch, Afrezza and the cash behind commercial growth
The full research covers Furoscix and ReadyFlow, pediatric Afrezza, Tyvaso DPI partner economics and competitive settlement, clinical pipeline, revenue, cash and burn, debt, milestones, share dilution, ownership, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.
$HUMAResearch as of October 29, 2026PDF · 21 pages
Humacyte: Symvess launch, dialysis evidence and the funding path
The full research covers Symvess, V012 and V007 dialysis evidence, the sBLA path, CTEV, hospital adoption, product sales, cash and burn, Avenue debt and conversion rights, completed financing, warrant dilution, ownership, filed litigation, listing requirements, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.
$NTLAResearch as of October 29, 2026PDF · 19 pages
Intellia: lonvo-z FDA review, launch access and the nex-z safety question
The full research covers lonvo-z and HAELO, FDA review and commercial access, nex-z development and liver safety, cash and burn, OrbiMed debt, share dilution, ownership, insider transactions, filed litigation, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.
$IRENResearch as of October 29, 2026PDF · 20 pages
IREN: Microsoft delivery, AI growth and the funding test
The full research covers Microsoft and Horizon acceptance, AI contracts and ARR, earnings, customer advances, cash commitments, debt and leases, dilution, ownership and voting rights, filed litigation, tax and customs contingencies, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.
$RCATResearch as of October 29, 2026PDF · 23 pages
RCAT: Steyr offer, delivery ramp and the production-to-cash test
The full research covers drones and maritime systems, revenue targets, earnings, cash flow, inventory, financing, debt and awards, acquisitions and the conditional Steyr offer, ownership, compensation, insider activity, filed proceedings, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.
$TLRYResearch as of October 30, 2026PDF · 24 pages
TLRY: BrewDog integration and the cash-conversion test
The full research covers beverages and medical cannabis, BrewDog, annual and Q1 results, cash flow and working capital, debt and credit restrictions, leases, dilution, governance and compensation, filed proceedings, regulatory frameworks, scenarios, sources and FAQ. Research as of October 30, 2026; regular-session market reference October 29, 2026.
$VTGNResearch as of October 20, 2026PDF · 14 pages
Vistagen: Fasedienol’s PALISADE Record, Trial Redesign and the Nasdaq Deadline
Contrasts fasedienol’s four PALISADE trials and the limits of open-label and subgroup analyses, then examines how cash consumption, financing needs and the Nasdaq bid-price deadline constrain another controlled trial.
$CRMDResearch as of October 19, 2026PDF · 13 pages
CorMedix: DefenCath Reimbursement, REZZAYO Prophylaxis and Cash Collateral
Connects DefenCath’s post-TDAPA pricing reset with the ReSPECT prophylaxis evidence for REZZAYO, showing why customer rebates, collateral requirements and acquisition-related obligations matter even when reported earnings and operating cash flow are positive.
$PLTRResearch as of October 29, 2026PDF · 17 pages
Palantir: AIP Revenue Conversion, Army Contracts and Per-Share Economics
Explores how AIP deployments become recurring revenue, distinguishes Army purchasing ceilings from funded work, and weighs cash conversion against cloud spending commitments, equity compensation and founder voting control.
$VKTXResearch as of October 28, 2026PDF · 15 pages
Viking Therapeutics: VK2735, VANQUISH/SUNRISE and Convertible Financing
Covers injectable VK2735 maintenance results, the VANQUISH and oral SUNRISE programs, and the financing behind late-stage obesity development, separating trial completion expectations from readout dates and potential dilution.
$LUNRResearch as of October 29, 2026PDF · 17 pages
Intuitive Machines: Lanteris Satellite Orders, IM-3 and Backlog Conversion
Tracks the Lanteris satellite business alongside IM-3 and lunar relay development, explaining why backlog authorizations, contract costs, customer collections and acquisition spending determine whether a larger revenue base reduces financing dependence.
$KTOSResearch as of October 28, 2026PDF · 15 pages
Kratos: Funded Orders, AN/SPY-1 Expansion and Cash Conversion
Examines funded backlog versus opportunity pipeline, AN/SPY-1 and Helios capacity investment, and engine-development partnerships, testing whether acquisitions, working capital and production spending translate into profitable deliveries and collected cash.
$SANAResearch as of October 24, 2026PDF · 13 pages
Sana Biotechnology: UP421, SC451 Translation and the Funding Bridge
Separates the single-patient UP421 observation from SC451’s distinct development program, then evaluates manufacturing preparation, the SG293 timetable and the equity financing needed to bridge clinical work and cash consumption.
$AUTLResearch as of October 26, 2026PDF · 12 pages
Autolus: AUCATZYL Manufacturing, Lupus Expansion and Credit Economics
Examines AUCATZYL’s launch funnel and manufacturing margins, the CARLYSLE lupus evidence, and how credit tranches, revenue-sharing payments and warrants affect the funding available for broader obe-cel development.
$PGENResearch as of October 28, 2026PDF · 14 pages
Precigen: PAPZIMEOS Collections, Launch Economics and AdenoVerse
Follows PAPZIMEOS from recognized sales to customer collections, connecting reimbursement and treatment delivery with receivables, debt service and the separate development opportunities in AdenoVerse and PRGN-2009, rather than equating quarterly profit with self-funding.
$SATLResearch as of October 29, 2026PDF · 15 pages
Satellogic: Merlin Commissioning, Satellite Sales and Repeat Revenue
Distinguishes Merlin’s launch and commissioning from commercial service, compares satellite transfers with recurring imagery revenue, and examines how contracted work, convertible debt and share issuance shape the economics of constellation expansion.
$MISTResearch as of October 13, 2026PDF · 17 pages
Milestone Pharmaceuticals: CARDAMYST Uptake, ReVeRA-301 and Royalty Financing
Looks beyond CARDAMYST’s covered-lives statistics to reimbursed prescriptions and collected sales, while separating ReVeRA-301’s AFib-RVR development from the PSVT franchise and tracing the claims created by convertible notes and royalty financing. Research label: October 13; includes October 19 and 28 updates.
$ADMAResearch as of October 15, 2026PDF · 14 pages
ADMA Biologics: ASCENIV Growth, BIVIGAM Weakness and Debt-Funded Buybacks
Analyzes divergent ASCENIV and BIVIGAM sales trends, manufacturing-yield improvements and the revenue recovery embedded in guidance, alongside the borrowing and cash-collection tradeoffs behind accelerated share repurchases and capital returns. News label: October 15; also includes the November 4 earnings notice.
$NAUTResearch as of October 27, 2026PDF · 17 pages
Nautilus Biotechnology: Voyager, Tau Proteoforms and ATM Dilution
Connects the Tau proteoform study with paid Early Access services and Voyager’s instrument roadmap, examining the adoption hurdle, limited initial revenue and dilution implied by a potentially large ATM financing program.
$LASEResearch as of October 28, 2026PDF · 16 pages
Laser Photonics: Beamer Orders, LSAD Counter-Drone Development and Warrants
Reviews Beamer and CMS Laser’s industrial sales opportunities alongside LSAD counter-drone development, showing how delivery margins, affiliate arrangements, negative working capital and equity-linked financing influence the value retained by common shareholders.
$ABEOResearch as of October 30, 2026PDF · 15 pages
Abeona Therapeutics: ZEVASKYN Manufacturing, Reimbursement and Launch Conversion
Follows ZEVASKYN from patient preparation through manufacturing release and reimbursed treatment, explaining why center expansion and early sales do not automatically resolve yield constraints, operating losses or financing dependence.
$BCRXResearch as of October 29, 2026PDF · 15 pages
BioCryst: ORLADEYO, Astria’s Navenibart and Royalty Financing
Explores ORLADEYO’s growth and formulation expansion, the Astria acquisition’s navenibart program, and the distinction between reported profitability and retained cash after royalty financing, secured debt and one-time partnership proceeds. News: October 29; editorial review: October 4; previous full review: September 9.
$FLYResearch as of October 28, 2026PDF · 14 pages
Firefly Aerospace: Blue Ghost, SciTec and the Liquidity Covenant
Links Blue Ghost mission accounting and launch development with SciTec’s defense software business, then examines backlog termination rights, cash consumption and the minimum-liquidity covenant that limits apparent financing flexibility.
$ONCYResearch as of October 20, 2026PDF · 15 pages
Oncolytics: Pelareorep, REO 033 Colorectal Evidence and ATM Financing
Compares pelareorep’s colorectal and GOBLET evidence, separates randomized comparisons from small response cohorts, and explains how evaluable-patient timing, a limited cash reserve and ATM share sales interact in the development plan. News label: October 20; includes the October 27 GOBLET update.
$IRDResearch as of October 29, 2026PDF · 15 pages
Opus Genetics: Viatris Presbyopia Economics, LCA5/BEST1 and Oberland Debt
Separates the Viatris presbyopia partnership’s milestones and royalties from LCA5 and BEST1 retinal gene-therapy evidence, assessing how trial execution, Oberland financing conditions, warrants and conversion rights affect common-share economics.
$AGENResearch as of October 12, 2026PDF · 16 pages
Agenus: BOT+BAL Evidence, ROBBIN and Conditional PIPE Funding
Separates ovarian follow-up and neoadjuvant pathologic-response datasets from prospective ROBBIN evidence, while examining access-program collections, encumbered royalty economics and the difference between completed PIPE proceeds and cash dependent on warrant exercise. Review label: October 12; includes later October updates.
$IMUXResearch as of October 29, 2026PDF · 16 pages
Immunic: Vidofludimus, ENSURE and Warrant Financing
Vidofludimus calcium’s multiple sclerosis evidence across ENSURE, CALLIPER and extension studies, including endpoint and selection-bias questions. The financial sections examine cash burn, February financing terms and the dilution mechanics of warrants and the reverse split.
$SOUNResearch as of October 25, 2026PDF · 12 pages
SoundHound AI: LivePerson Integration, OASYS Edge and Cash Conversion
LivePerson integration and OASYS Edge’s deployment path are examined alongside SoundHound’s subscription and service economics. The report separates revenue growth from collections, acquisition commitments and the cash costs borne by existing shareholders.
$TGTXResearch as of October 21, 2026PDF · 17 pages
TG Therapeutics: BRIUMVI Sales, Subcutaneous Development and Blue Owl Debt
BRIUMVI’s commercial ramp, ULTIMATE evidence and subcutaneous development are set against the economics of the Blue Owl loan. The report also examines buybacks, launch spending and competition within the anti-CD20 market. Date label: October 21; includes October 23 updates.
$RAREResearch as of October 19, 2026PDF · 15 pages
Ultragenyx: FAYUVI, GENGLYCOS and the Cost of Pipeline Setbacks
Examines the FAYUVI and GENGLYCOS launch opportunities alongside pivotal pipeline setbacks, distinguishing recognized royalty revenue from retained cash and testing how restructuring, commercial execution and royalty-sale obligations affect the funding path.
$PDYNResearch as of October 29, 2026PDF · 15 pages
Palladyne AI: Autonomy Orders, SwarmShot Development and Cash Burn
Distinguishes contracted delivery work from SwarmShot development and military competitions, then relates backlog conversion and revenue guidance to acquisition economics, cash burn and the share issuance supporting Palladyne’s autonomy business.
$GUTSResearch as of October 30, 2026PDF · 15 pages
Fractyl Health: Revita’s REMAIN-1 Endpoints, De Novo Plans and the Reverse Split
Contrasts Revita’s pilot and pivotal six-month evidence with the outstanding one-year endpoint and planned De Novo submission, then examines cash consumption, financing choices and what the reverse split changes for shareholders.
$SIDUResearch as of October 29, 2026PDF · 14 pages
Sidus Space: LizzieSat Delays, Fortis and the Cash Bridge
How LizzieSat’s launch schedule, Fortis computing qualification and the Slovenian memorandum connect to potential sales. Revenue recognition, customer concentration, recurring cash consumption and financing through shares and warrants frame the gap between development and commercial scale.
$EYPTResearch as of October 30, 2026PDF · 17 pages
EyePoint: DURAVYU, LUCIA and the DME Funding Test
DURAVYU’s wet AMD results and the COMO/CAPRI diabetic macular edema program, including noninferiority endpoints, supplemental injections and manufacturing requirements. Cash consumption and remaining clinical costs frame the financing challenge behind another pivotal program.
$CELCResearch as of October 29, 2026PDF · 16 pages
Celcuity: REVTORPYK Launch, VIKTORIA-1 and Pfizer Economics
REVTORPYK’s label, VIKTORIA-1 efficacy and tolerability, and the commercial launch are examined alongside Pfizer milestone and royalty obligations. The balance-sheet discussion explains how convertible financing and launch costs affect shareholder economics.
$APLDResearch as of October 24, 2026PDF · 17 pages
Applied Digital: Campus Leases, Project Debt and Preferred Equity
The bridge from contracted AI campus capacity to rental income, including construction milestones, tenant concentration and fit-out accounting. Project debt, restricted cash and preferred-equity distributions show which cash flows reach common shareholders.
$PLResearch as of October 21, 2026PDF · 17 pages
Planet Labs: Pelican, Government Contracts and Fleet Financing
Government demand, backlog conversion and Berlin satellite production are linked to Planet’s next fleet investment cycle. The report examines working capital, convertible debt, capped calls and equity issuance to distinguish reported growth from cash available for expansion.
$AXSMResearch as of October 26, 2026PDF · 20 pages
Axsome Therapeutics: AUVELITY, AXS-12 and the Cost of Commercial Growth
AUVELITY’s Alzheimer’s agitation launch, the AXS-12 regulatory path and the roles of SUNOSI and SYMBRAVO. Selling expenses, Blackstone borrowing and the Antecip royalty arrangement explain the financial demands of a broader neuroscience franchise.
$SVRAResearch as of October 21, 2026PDF · 36 pages
Savara: MOLBREEVI, IMPALA-2 and Conditional Debt
MOLBREEVI’s regulatory sequence and IMPALA-2 endpoints, with close attention to manufacturing questions and the limits of the reported evidence. Conditional borrowing, royalty obligations and outstanding warrants explain how development outcomes change Savara’s financing position.
$SPCXResearch as of October 30, 2026PDF · 18 pages
SpaceX: Starlink, AI Compute Contracts and the Capital Spending Bill
Starlink subscriber economics, launch operations and AI compute contracts across SpaceX’s combined businesses. Cash generation is separated from capital spending, equipment financing and acquisition shares, while customer concentration and cancellation terms shape the revenue analysis.
$RXRXResearch as of October 26, 2026PDF · 16 pages
Recursion Pharmaceuticals: REC-4881, TUPELO and Collaboration Economics
REC-4881 and the small TUPELO dataset in familial adenomatous polyposis anchor the clinical discussion. Roche, Sanofi and Tempus agreements are examined through milestone accounting, data costs and the interplay between pipeline spending and equity financing.
$VNDAResearch as of October 28, 2026PDF · 18 pages
Vanda Pharmaceuticals: HETLIOZ, Imsidolimab and the Commercial Cash Test
HETLIOZ’s delayed sleep-phase study, imsidolimab’s regulatory path and the mix of Fanapt, PONVORY and newer products. Revenue timing, launch execution and historical liquidity connect the clinical portfolio to the cost of building sales.
$ARWRResearch as of October 27, 2026PDF · 15 pages
Arrowhead: REDEMPLO Sales, ARO-MAPT and Partnership Cash
REDEMPLO’s launch economics and SHASTA evidence sit alongside ARO-MAPT biomarker findings and the broader RNA interference pipeline. Partnership receipts, the priority review voucher, debt covenants and committed spending explain the uneven pattern of cash generation.
$CADLResearch as of October 29, 2026PDF · 17 pages
Candel Therapeutics: Prostate Phase 3, BLA Manufacturing and Conditional Funding
Aglatimagene’s prostate trial evidence and manufacturing validation connect to the proposed BLA pathway, with AURORA and linoserpaturev providing separate development questions. Spending, equity dilution and financing contingent on approval frame the cost of advancing the platform.
$PLXResearch as of October 12, 2026PDF · 14 pages
Protalix: Elfabrio Partner Terms, PRX-115 and Working Capital
Elfabrio’s partner economics, Elelyso sales and the PRX-115 gout program define Protalix’s business mix. Inventory, receivables, milestone income and equity financing are examined to explain the difference between accounting profit and cash available for development.
$CGCResearch as of October 26, 2026PDF · 14 pages
Canopy Growth: Medical Cannabis, MTL and the Funding Gap
The Canadian medical reset and MTL business perimeter, alongside Canopy USA’s separate regulatory and accounting position. Excise taxes, inventory discipline, debt covenants and equity issuance frame the gap between adjusted EBITDA and operating cash.
$CINGResearch as of October 4, 2026PDF · 16 pages
Cingulate: CTx-1301, CMC Remediation and Launch Funding
CTx-1301’s release technology, clinical evidence and manufacturing remediation after the FDA response letter. The report examines launch infrastructure, cash consumption and potential equity issuance without treating a resubmission plan as a dated regulatory decision.
$ABVXResearch as of October 17, 2026PDF · 14 pages
Abivax: Obefazimod, ABTECT Maintenance and the Royalty Buyback
Obefazimod’s ABTECT induction and maintenance evidence, with responder selection, dosing, safety and NDA preparation. June liquidity, July equity proceeds and the buyback of royalty certificates show how clinical spending and financing affect cash and shareholder dilution.
$UMACResearch as of October 9, 2026PDF · 13 pages
Unusual Machines: Drone Components, Upgrade Energy and Working Capital
Domestic drone component production, factory expansion and the Upgrade Energy transaction are examined through inventory, receivables and customer qualification. Cash committed before delivery connects to ATM financing, strategic investments and the economics of management awards. Date label: October 9; includes October 23 updates.
$IVAResearch as of October 23, 2026PDF · 24 pages
Inventiva: NATiV3, Lanifibranor and the Warrant Dilution Map
Lanifibranor’s Phase 2b foundation and NATiV3’s biopsy endpoints, cohort definitions and readout framework. The financing analysis tracks EIB refinancing, secured debt and warrant triggers that link clinical timing to cash needs and potential dilution.
$PYPDResearch as of October 29, 2026PDF · 43 pages
PolyPid: D-PLEX100, SHIELD II and Azurity Payment Terms
D-PLEX100’s SHIELD I and SHIELD II evidence, the regulatory sequence and manufacturing responsibilities. The financial analysis follows historical cash, prelaunch inventory and Azurity payment conditions to test how commercialization could be funded.
$ABCLResearch as of October 30, 2026PDF · 19 pages
AbCellera: ABCL635, Jazz Collaboration and the Cash Runway
ABCL635’s clinical evidence and ABCL575’s development plans sit beside the Jazz collaboration on multispecific antibodies. Cash burn, restricted balances, public funding and equity issuance are separated to assess how the proprietary pipeline is financed.
$CGTXResearch as of October 22, 2026PDF · 17 pages
Cognition Therapeutics: zervimesine, DLB trial design and START
Zervimesine’s DLB and Alzheimer’s programs, the exploratory SHIMMER and SHINE findings, planned registrational endpoints and START are examined alongside grant support, cash consumption, ATM dilution, manufacturing and the evidence needed for pivotal development.
$CRMLResearch as of October 28, 2026PDF · 16 pages
Critical Metals: Tanbreez, European Lithium and project funding
Tanbreez’s permitting and processing route, the European Lithium exchange terms, Wolfsberg and the proposed Romanian refinery are assessed against FY2026 cash, binding offtake, warrants, transaction shares and the distinction between project models and shareholder returns.
$TENXResearch as of October 12, 2026PDF · 17 pages
Tenax Therapeutics: LEVEL failure, revised enrollment and the cash-versus-dilution question
LEVEL’s missed endpoints, the temporary LEVEL-2 enrollment pause and the requested FDA discussion frame this analysis of levosimendan. It separates June cash, continuing spending, pre-funded warrants and dated ownership from prospects for prospective clinical confirmation.
$SNDXResearch as of October 30, 2026PDF · 16 pages
Syndax Pharmaceuticals: Revuforj, Niktimvo and the clinical-versus-commercial balance
Two approved medicines anchor Syndax’s commercial base, while MAXPIRe’s IPF failure and frontline cGVHD studies test indication expansion. The report separates product revenue, collaboration income, June liquidity, royalties and convertible obligations when assessing retained shareholder economics.
$ATYRResearch as of October 29, 2026PDF · 14 pages
aTyr Pharma: the next efzofitimod trial, financing and the reverse split
EFZO-FIT’s missed primary endpoint frames aTyr’s new pulmonary-sarcoidosis study and separate EFZO-CONNECT readout. The report examines June resources, restructuring, additional Phase 3 financing, the October reverse split and early ATYR0101 and ATYR2810 development.
$RCKTResearch as of October 16, 2026PDF · 15 pages
Rocket Pharmaceuticals: the Danon restart, Kresladi and the funding bridge
RP-A501’s revised Danon trial must pair durable responses with acceptable safety. This report examines its pivotal design, Kresladi commercialization, voucher-funded June liquidity, conditional Hercules borrowing, ongoing cash consumption and the instruments affecting per-share exposure.
$AVAVResearch as of October 16, 2026PDF · 14 pages
AeroVironment: funded orders, BlueHalo integration and the path to cash
Funded backlog and defense contracts support AeroVironment’s growth case, while deliveries, margins and working capital determine cash conversion. The report examines Switchblade, counter-UAS systems, BlueHalo integration, accounting controls, liquidity and dilution alongside dated market opinions. Date label: October 16; includes October 19 and 22 updates.
$ALDXResearch as of September 30, 2026PDF · 16 pages
Aldeyra Therapeutics: the reproxalap appeal, cash runway and the next NDA steps
Aldeyra’s planned formal appeal of the reproxalap CRL is distinct from a subsequent NDA resubmission or approval. The report examines the evidence dispute, ADX-2191, AbbVie optionality, June cash, operational runway and future dilution. News label: September 30; Health Score assessed October 4.
$ASTSResearch as of October 30, 2026PDF · 20 pages
AST SpaceMobile: deployment, spectrum and recurring-service economics
Constellation deployment, operator distribution and spectrum rights are examined alongside the gap between equipment revenue and recurring service, heavy capital expenditure, restricted cash, Ligado conditions, convertible debt and the cost of scaling a satellite network. News label: October 30; original financial, market and assessment dates retained.
$RIOTResearch as of October 21, 2026PDF · 14 pages
Riot Platforms: AMD delivery, AI leases and the financing bridge
Riot’s shift from Bitcoin mining toward AI infrastructure is examined through AMD capacity deliveries, the larger long-term lease, recurring rent versus tenant fit-out, construction costs, cash and Bitcoin reserves, debt maturities and per-share financing risk.
$BMEAResearch as of October 13, 2026PDF · 17 pages
Biomea Fusion: BMF-650, icovamenib and the financing deadline
BMF-650’s outpatient weight-loss findings and confined-cohort limitations are examined alongside icovamenib’s diabetes studies, the menin hypothesis, historical cash consumption, the going-concern warning, cancelled financing, potential dilution and the December warrant expiry.
$CTMResearch as of October 28, 2026PDF · 16 pages
Castellum: Navy contract funding, backlog and delivery margins
Navy PMA-290, ADMACS and LIIS opportunities are separated into funded work, ceilings and competition rights. The analysis connects delivery margins, adjusted EBITDA, receivables, cash, obligations and equity incentives to the contractor’s operating performance.
$IRONResearch as of October 23, 2026PDF · 16 pages
Disc Medicine: APOLLO, bitopertin and financing the regulatory path
APOLLO topline findings, the earlier FDA deficiency and the planned bitopertin resubmission frame Disc’s hematology pipeline. The report distinguishes June liquidity, Hercules borrowing, October offering proceeds, licensing obligations and potential dilution from regulatory success. Date label: October 23; includes October 26 updates.
$PDSBResearch as of October 29, 2026PDF · 14 pages
PDS Biotechnology: PDS0301 signals, strategic funding and warrant exposure
PDS0301’s nonrandomized colorectal evidence and prostate data windows are assessed alongside the PDS0101 strategic reset. June cash, September PIPE conditions, debt redemption, resale registration and pre-funded warrants explain why financing and clinical confirmation remain separate tests.
$SENSResearch as of October 27, 2026PDF · 17 pages
Senseonics: Eversense adoption, pump integration and commercial cash use
Eversense 365 commercialization, pump partnerships, real-world evidence and the Gemini and Freedom pipeline are examined against revenue growth and raised guidance. The financial analysis separates unrestricted liquidity, Hercules debt, cash consumption, pre-funded warrants and issuance capacity.
$BCDAResearch as of October 21, 2026PDF · 18 pages
BioCardia: Helix, the CardiAMP Japan route and a narrow equity cushion
BioCardia’s Helix feedback package and CardiAMP Japan submission plans meet a narrow equity cushion and an exhausted June ATM. The report examines trial limitations, confirmatory enrollment, cash runway, warrants and financing scenarios.
$MDGLResearch as of October 20, 2026PDF · 17 pages
Madrigal: Rezdiffra adoption, MASH outcomes and the cost of expansion
Rezdiffra’s commercial adoption meets continuing losses, confirmatory outcomes obligations and a growing combination pipeline. The report examines June revenue, patients, liquidity and debt, alongside cirrhosis research, licensing commitments, competitive mechanisms and treatment persistence. Last review: October 20; research-update label: October 6; separate October 27 news retained.
$ZURAResearch as of October 27, 2026PDF · 18 pages
Zura Bio: tibulizumab endpoints, cash and pre-funded dilution
Tibulizumab’s IL-17A and BAFF rationale, TibuSHIELD and TibuSURE trial endpoints, shared clinical risks, historical cash, pre-funded warrants and the separately dated October shelf and quarterly updates explain the development and financing case.
$XXIIResearch as of October 29, 2026PDF · 18 pages
22nd Century: Pinnacle distribution, MRTP renewal and ATM dilution
Pinnacle’s retail expansion and Gopuff agreement are examined alongside tobacco regulation, MRTP renewal, preliminary quarterly results, operating cash use, abeyance shares, warrant mechanics and ATM financing that shape the company’s fragile per-share economics. News label: October 29; original financial, market and assessment dates retained.
$MRNAResearch as of October 27, 2026PDF · 13 pages
Moderna: melanoma evidence, respiratory vaccines and the capital bridge
Moderna’s detailed INTerpath-001 melanoma results sit alongside respiratory-vaccine economics and substantial spending. The report examines clinical durability, June liquidity, convertible financing, settlement costs, shared oncology economics and the regulatory path toward commercialization.
$OGIResearch as of October 15, 2026PDF · 13 pages
Organigram: Sanity growth, cash conversion and fixed acquisition consideration
Sanity expands Organigram’s European medical business, but non-cash preferred-share gains dominate quarterly net income. The report separates Canadian-dollar operating results, working capital, biological fair values, liquidity, integration savings and fixed acquisition consideration.
$CMPSResearch as of October 28, 2026PDF · 13 pages
Compass Pathways: COMP360 filing, supervised treatment and warrants
COMP360’s controlled Phase 3 results and open-label follow-up are examined alongside NDA completion, safety monitoring, supervised-treatment delivery, provider preparation, historical cash consumption, warrants and the conditions required for an eventual commercial launch.
$CYTKResearch as of October 22, 2026PDF · 16 pages
Cytokinetics: MYQORZO launch, two regulatory paths and capital claims
MYQORZO’s obstructive launch and non-obstructive evidence face separate regulatory steps. The report examines MAPLE and ACACIA results, safety, early revenue, historical liquidity, operating cash use, negative equity, royalty obligations and dilution. Editorial review: October 22; individual news and data dates retained.
$ARTVResearch as of October 29, 2026PDF · 20 pages
Artiva: AlloNK discontinuation, strategic alternatives and residual resources
Artiva’s AlloNK discontinuation and strategic review supersede earlier clinical plans. The report preserves safety and durability disclosures, preliminary September resources, the wind-down filing, historical financing, dilution and the limits of assuming a liquidation return. Editorial review: October 29; separate October 27 company-news label retained.
$PROKResearch as of October 29, 2026PDF · 19 pages
ProKidney: PROACT 1 evidence, Kidney Week and the funding gap
Rilparencel’s autologous kidney-cell approach, Phase 2 limitations and PROACT 1 design frame the pivotal eGFR test. Kidney Week abstracts, going-concern uncertainty, June liquidity, paired share classes, the October shelf and dilution shape the financing case.
$RGNXResearch as of October 29, 2026PDF · 17 pages
REGENXBIO: retinal trials, regulatory setbacks and the funding bridge
Sura-vec retinal evidence, the RGX-121 hold and RGX-202 development are separated from regulatory success. June liquidity, July milestone and offering proceeds, Sarepta’s settlement obligation, royalties and cash consumption frame the financial and clinical scenarios.
$ANNXResearch as of October 28, 2026PDF · 15 pages
Annexon: ARCHER II stages, GBS evidence and financing conditions
ARCHER II’s functional endpoint and staged analyses are assessed alongside the earlier ARCHER failure, ocular safety, GBS evidence and ANX1502. June liquidity, Oxford borrowing, conditional tranches, warrants and spending distinguish development capacity from clinical success. Last review: October 28; information-current label: October 19.
$RAPPResearch as of October 28, 2026PDF · 19 pages
Rapport: RAP-219 mania findings, epilepsy evidence and capital structure
RAP-219’s bipolar-mania result and uncontrolled epilepsy evidence face different standards for confirmation. The analysis connects pivotal plans, long exposure, June cash, conditional partnership economics, the October offering terms, convertibles and warrants to future funding needs. Last review: October 28; earlier October 23 review label retained.
$ACBResearch as of October 29, 2026PDF · 16 pages
Aurora Cannabis: medical growth, cash conversion and the Curaleaf offer
International medical sales, like-for-like comparisons and production expansion are separated from cash generation. June liquidity restrictions, working capital, ATM capacity, governance and Curaleaf’s cash-and-share bid explain the competing operating, financing and transaction risks.
$CORTResearch as of October 27, 2026PDF · 17 pages
Corcept: Lifyorli launch, BELLA evidence and the Cushing’s application
Lifyorli’s initial commercial contribution, Korlym’s revenue base, BELLA and ROSELLA evidence, the separate relacorilant Cushing’s application, European review, launch spending and dated liquidity frame Corcept’s operating opportunity and regulatory risks. Review label: October 27 in the original markup; dated references retained.
$OKLOResearch as of October 28, 2026PDF · 14 pages
Oklo: Aurora authorization, nuclear fuel and construction economics
Aurora’s path from authorization to operating power is examined through Groves isotope milestones, fuel supply, customer commitments, construction spending, historical liquidity and the equity issuance that can finance development while diluting shareholders.
$VRDNResearch as of October 21, 2026PDF · 16 pages
Viridian: Lumvoa access, elegrobart and royalty-financed launch economics
Lumvoa’s approval and early launch are examined through payer criteria, elegrobart’s development path, FcRn programs, competing treatment routes, historical liquidity, royalty financing and convertible claims that affect the economics retained by common shareholders.
$ZVRAResearch as of October 24, 2026PDF · 13 pages
Zevra: MIPLYFFA cash generation and European evidence review
MIPLYFFA’s U.S. sales and patient access are examined alongside operating cash generation, debt repayment, European re-examination, long-term NPC evidence, celiprolol’s development path and potential dilution despite the stronger dated balance sheet.
$BHVNResearch as of October 29, 2026PDF · 16 pages
Biohaven: BHV-1530 evidence, partial hold and licensing cash
BHV-1530’s early oncology observations are examined alongside neuroscience and immunology programs, opakalim’s partial enrollment hold, licensing agreements, quarterly cash and debt, pending contractual payments and the dilution required to fund a broad clinical portfolio.
$FCELResearch as of October 29, 2026PDF · 15 pages
FuelCell Energy: Fit deliveries, factory costs and financing dilution
Fuel-cell production growth is examined through Fit’s committed and optional phases, early contract losses, factory investment, installed-project performance, historical unrestricted and restricted cash, financing obligations and the share issuance funding the manufacturing transition.
$BKSYResearch as of October 22, 2026PDF · 15 pages
BlackSky: Gen-3 subscriptions, SkyFi distribution and cash conversion
Gen-3 imaging and subscriptions are examined alongside SkyFi distribution, sovereign-system contracts, constellation deployment, contract-estimation risk, historical cash conversion, debt and equity issuance that determine how much operating growth reaches each common share.
$CMPXResearch as of October 24, 2026PDF · 14 pages
Compass Therapeutics: tovecimig endpoints and the survival-evidence gap
COMPANION-002’s response and progression findings are examined beside its non-significant survival result and FDA feedback. The report distinguishes crossover analyses, safety, early antibody programs, June resources and the financing implications of additional clinical evidence.
$CRONResearch as of October 21, 2026PDF · 14 pages
Cronos: product profitability, treasury resources and CanAdelaar conditions
Cronos’ product growth and operating profit are separated from treasury returns and currency effects. The report examines Dutch acquisition terms, unresolved regulatory conditions, capped indemnities, repurchases and the maturity and obligations attached to historical resources.
$AQSTResearch as of October 27, 2026PDF · 26 pages
Aquestive: Anaphylm review, launch preparation and conditional funding
Anaphylm’s regulatory history, usability and pharmacokinetic studies are examined alongside commercial readiness, Libervant licensing, manufacturing revenue and financing conditions. The report separates approval-contingent resources, future-revenue obligations, dilution and the risks of a first branded launch. Editorial date: October 27, recorded in the original markup; older visible labels and September 18 Health Score remain separately dated.
$FATEResearch as of October 26, 2026PDF · 16 pages
Fate Therapeutics: FT819 renal evidence, RECLAIM-LN and share claims
FT819’s small, uncontrolled renal observations frame the separate RECLAIM-LN trial. The report examines conditioning safety, FT839 development, manufacturing, June resources, the CIRM award, preferred-share equivalents, warrants and the financing required for extended enrollment.
$UAMYResearch as of October 26, 2026PDF · 15 pages
United States Antimony: shipment acceptance, Nolan Creek and cash conversion
Follows the antimony supply chain from feedstock and processing through DLA shipment, sampling, customer acceptance and cash collection, explaining why a delivery pipeline is not recognized revenue. The financial analysis separates cash, Treasury holdings, equity investments and conditional grants, then examines operating consumption, expansion commitments, ATM issuance and the buyback authorization. Zeolite operations and development-stage mineral projects provide context for the central risks of pricing, recovery, execution and dilution.
$CRSPResearch as of October 28, 2026PDF · 14 pages
CRISPR Therapeutics: CASGEVY economics, CTX310 and the funding bridge
Connects CASGEVY’s commercial progress and pediatric label expansion with the Vertex profit-and-loss sharing arrangement, treatment logistics and continuing collaboration costs. Separate clinical chapters assess CTX310’s lipid-lowering biomarkers, the small zugo-cel datasets and additional development programs without equating early activity with durable clinical outcomes. The report also traces the cash reserve, operating expenditure, convertible financing, equity compensation and future issuance capacity that shape the cost of advancing the pipeline.
$AUPHResearch as of October 30, 2026PDF · 16 pages
Aurinia: Lupkynis growth, cash generation and capital allocation
Examines how LUPKYNIS sales and operating cash generation support Aurinia’s shareholder case, while distinguishing product growth from the cash retained after buybacks, equity awards and other commitments. The Teva settlement is assessed within its specific generic-entry limits, and the clinical discussion separates established AURORA evidence from PRESERVE and aritinercept development. Manufacturing leases, the Kezar transaction and contingent rights complete the analysis of franchise concentration, capital allocation and future spending.
$OSSResearch as of October 28, 2026PDF · 17 pages
One Stop Systems: rugged edge AI, production and cash conversion
Places rugged edge computing in the practical settings OSS serves, from defense platforms and GNSS simulation to autonomous equipment and medical imaging. Tamarack-G product development, repeat orders and the narrower business after the Bressner sale are connected to bookings, revenue conversion and margins. The financial sections examine the legal settlement, inventory buildup, supplier and customer concentration, cash availability and equity-financing capacity, emphasizing that a qualification or order announcement does not by itself establish profitable delivery.
$PACBResearch as of October 20, 2026PDF · 17 pages
PacBio: HiFi demand, consumables and convertible financing
Investigates whether Revio, Vega and SPRQ-Nx can turn lower sequencing costs into greater sample demand and recurring consumables revenue. Five quarters of operating evidence, instrument placements, pull-through, revenue mix and the reduced annual outlook help distinguish technological progress from commercial recovery. Cash use, restructuring, convertible maturities and the PGI settlement are analyzed alongside competitive pressures, dilution and the funding required to make the focused HiFi sequencing business sustainable.
$RNXTResearch as of October 22, 2026PDF · 13 pages
RenovoRx: device adoption, survival evidence and funding conditions
Separates RenovoCath device commercialization from the investigational drug-delivery combination being tested in TIGeR-PaC. Early pancreatic-cancer observations and trial milestones are assessed without substituting uncontrolled findings for the randomized survival result. The report then follows device sales, operating expenditure, cash and runway assumptions, outstanding shares, warrants and financing capacity, connecting the clinical timetable with the commercial and capital needs that could change the company’s position before definitive evidence arrives.
$BBOTResearch as of October 21, 2026PDF · 16 pages
BridgeBio Oncology: RAS combinations, early trials and dilution
Maps BBO-8520, BBO-11818 and BBO-10203 across RAS and PI3Kα biology, focusing on the logic of internal combinations and the limits of small Phase 1 datasets. Early response evidence is considered alongside dose finding, safety, durability and the distinction between monotherapy and combination updates. Financial chapters trace liquidity, development spending, runway guidance, the public-market structure, resale overhang and equity dilution, showing how funding supports experimentation without removing shared biological risk.
$IMRXResearch as of October 29, 2026PDF · 14 pages
Immuneering: pancreatic survival, MAPKeeper 301 and the cash runway
Assesses atebimetinib’s pancreatic-cancer survival signal and exploratory analyses while explaining why longer follow-up and a controlled comparison remain essential. MAPKeeper 301’s enrollment plan, the expanded patient target and the separate lung-cancer program are placed on distinct evidence timelines. September financial resources, historical operating cash use and runway guidance are reconciled with warrants, share issuance and financing capacity, linking the clinical development plan to the capital needed to complete it.
$NVOResearch as of October 28, 2026PDF · 17 pages
Novo Nordisk: GLP-1 growth, CagriSema and capital allocation
Reviews Novo Nordisk’s obesity and diabetes franchises alongside oral Wegovy, CagriSema, zenagamtide, MASH and rare-disease development. Clinical and regulatory opportunities are weighed against competition, access, pricing, manufacturing investment and product concentration. The financial analysis distinguishes reported from adjusted growth, examines cash flow, debt and capital returns, and keeps Danish-krona accounts separate from the US-dollar ADR, providing a framework for judging whether a larger treatment market can translate into durable shareholder economics.
$USASResearch as of October 23, 2026PDF · 15 pages
Americas Gold and Silver: mine upgrades, operating cash and covenants
Connects Galena and Cosalá production, mine upgrades and drilling opportunities with the output, cost and collection improvements needed to support growth. The June financial analysis reconstructs cash movements, distinguishes operating cash generation from investment spending, and examines debt, covenant requirements and restricted balances. Warrants, share issuance and silver-price exposure complete the risk discussion, keeping exploration potential and annual guidance separate from achieved production, sustainable margins and cash available to shareholders.
$LEGNResearch as of October 27, 2026PDF · 20 pages
Legend Biotech: CARVYKTI economics, durability and the LB2501 evidence
Explains how CARVYKTI sales reach Legend through its collaboration economics, connecting commercial growth with the company’s income statement and cash flow. Long-term CARTITUDE evidence, frontline trial design and neurological safety are examined alongside the much smaller, early LB2501 dataset and the pipeline beyond CARVYKTI. Balance-sheet resources, financing and dilution are considered with manufacturing, treatment access and competition, while ADS arithmetic prevents ordinary shares and depositary units from being treated as interchangeable.
$LARResearch as of October 26, 2026PDF · 15 pages
Lithium Argentina: Cauchari-Olaroz, Stage 2 and the financing structure
Follows Cauchari-Olaroz production and the cash available to Lithium Argentina through its joint-venture interest, explaining the difference between project operations, equity-method earnings and parent-company distributions. Stage 2 study economics, direct-lithium-extraction work and the Salta development path are examined with permitting, partner governance and capital commitments. Corporate liquidity, strategic convertible financing and the repurchase of older notes complete the analysis of expansion funding, lithium-price sensitivity and execution risk.
$LPTHResearch as of October 27, 2026PDF · 16 pages
LightPath Technologies: imaging orders, backlog and acquisition cash claims
Examines LightPath’s shift toward infrared imaging, including BlackDiamond materials, CLEAR technology and the acquired businesses behind its larger revenue base. Backlog is tested against delivery schedules, manufacturing yields, customer concentration and the ability to turn orders into collections. Cash consumption, working capital, expansion spending, G5 earnout payments, preferred stock and common-share issuance are considered together to show why a substantial cash balance does not eliminate execution or dilution risk.
$RDWResearch as of October 29, 2026PDF · 17 pages
Redwire: defense deliveries, space contracts and the cash-conversion test
Analyzes the enlarged Redwire after Edge Autonomy, distinguishing the economics of space hardware from defense products and uncrewed systems. Contract accounting, backlog conversion and segment margins are examined alongside Honda robotics, Sophia Space and microgravity initiatives, with research concepts separated from contracted business. The financing chapters follow cash, working capital, debt, preferred conversion and share issuance, while governance and litigation disclosures frame the risks of integrating acquisitions and delivering profitable growth.
$SRRKResearch as of October 27, 2026PDF · 28 pages
Scholar Rock: ISEMBYLD launch, fracture risk and conditional liquidity
Explores ISEMBYLD’s SMA approval through the SAPPHIRE evidence, the approved dose, nominal statistical findings and the limits of extrapolating from the studied population. Fracture warnings, post-marketing obligations and the company’s corrective disclosure receive detailed treatment alongside launch access, infusion logistics and the European regulatory path. June financial statements, the Blue Owl facility, minimum-cash requirements and ATM dilution show how a funded balance sheet intersects with the costs and uncertainties of commercialization.
$VCREResearch as of October 23, 2026PDF · 18 pages
Vicore Pharma: ASPIRE’s randomized test, IPF evidence and ADS claims
Sets buloxibutid’s uncontrolled AIR findings against the randomized ASPIRE Phase 2b design and the increasingly demanding treatment benchmarks in idiopathic pulmonary fibrosis. The discussion explains observed versus imputed lung-function results, safety, patent protection and the Japan partnership rather than treating an early signal as confirmed efficacy. Swedish-krona financials, operating cash use, runway assumptions and dilution are paired with the mechanics of the Nasdaq ADS listing, which itself raised no new capital.
$GPCRResearch as of October 20, 2026PDF · 16 pages
Structure Therapeutics: aleniglipron evidence, oral amylin and capital
Distinguishes aleniglipron’s pivotal program from the separate body-composition, diabetes and treatment-switch studies, then considers ACCESS extension findings and the earlier-stage oral amylin opportunity. Clinical maturity, follow-up and safety are weighed against competition in obesity rather than merged into a single efficacy claim. The financing analysis covers cash and investments, research spending, ADS mechanics, warrants and issuance capacity; the original Health assessment remains qualitative, with no numerical composite score.
$ZENAResearch as of October 28, 2026PDF · 17 pages
ZenaTech: drone-service growth, integration and funding risks
Dissects ZenaTech’s acquired survey-services network, enterprise software and drone-development businesses, which have different revenue bases and levels of maturity. The analysis separates growth within an acquisition cohort from consolidated expansion, and contrasts existing service work with defense qualification, prototype aircraft, agricultural systems and Stacklens development. Canadian-dollar financial statements, related-party advances, acquisition accounting and multiple equity instruments reveal the integration, liquidity and dilution risks behind the broader technology strategy.
$BEAMResearch as of October 28, 2026PDF · 19 pages
Beam Therapeutics: editing evidence, safety and the funding runway
Examines base editing across BEAM-302 in alpha-1 antitrypsin deficiency, risto-cel in sickle cell disease and the mutation-specific liver programs BEAM-301 and BEAM-304. Biomarker durability, clinical follow-up, conditioning, safety and manufacturing are separated from potential filing or accelerated-approval pathways. Cash and securities, development spending, conditional debt draws and ATM capacity frame the financing discussion, while the competitive analysis asks whether individual results can support a repeatable therapeutic platform.
$DFTXResearch as of October 29, 2026PDF · 18 pages
Definium Therapeutics: DT120 evidence, supervised treatment and the funding bridge
DT120’s pivotal evidence is examined across generalized anxiety disorder and major depression, with separate attention to Panorama, Voyage, Emerge and the Ascend replication study. The dossier discusses functional unblinding, long-term safety and retreatment, FDA preparation, controlled-substance scheduling and the capacity and reimbursement required for supervised dosing. June financing, cash consumption, employee options and the enlarged share base frame the resources and ownership risks behind that development path.
$PMVPResearch as of October 12, 2026PDF · 12 pages
PMV Pharmaceuticals: ovarian response evidence and the warrant reset
Examines rezatapopt’s ovarian-cancer response evidence, including confirmation, durability, safety and the limits of the PYNNACLE populations. June resources and operating cash use are reconciled with the September financing, management’s runway plan, pre-funded warrants and common-warrant adjustments tied to FDA acceptance. Clinical development, commercial preparation and ownership complete the discussion of regulatory uncertainty and dilution. Report label: October 12; underlying review attribute: September 23.
$ZNTLResearch as of October 23, 2026PDF · 15 pages
Zentalis: azenosertib survival evidence, DENALI and the financing bridge
Examines the WEE1 and Cyclin E1 hypothesis through DENALI’s response populations, survival follow-up, dose selection and safety, while separating single-arm findings from randomized ASPENOVA evidence. June financial resources are connected to the completed August offering, runway guidance, share count and licensing economics. Diagnostic deployment, treatment competition and the risks of translating selected clinical activity into an approved product complete the analysis.
$TRLVResearch as of October 20, 2026PDF · 15 pages
Trulieve: medical cash generation, Harvest accounting and legacy taxes
Explains the medical-cannabis platform after the Harvest separation, distinguishing consolidated results, retained interests, management fees and actual cash collection. Revenue, margins and free cash flow are tested against debt, leases, legacy tax disputes and capital allocation. Georgia expansion, Connected licensing, conditional Texas entry and the dated federal regulatory process frame the operating opportunities without turning procedural developments into final permissions or guaranteed shareholder returns.
$DPROResearch as of October 27, 2026PDF · 14 pages
Draganfly: defense orders, delivery economics and the funding structure
Draganfly’s Canadian procurement award is separated into the firm starting order, optional systems and the manufacturing work required for delivery. The report examines Heavy Lift and Commander platforms, autonomy investment, U.S. defense organization, supplier and acceptance risks, and the economics behind revenue and margins. Canadian-dollar accounts, inventory, operating cash consumption, the later U.S.-dollar financing and potential warrant or award dilution frame the funding and ownership questions.
$NVDAResearch as of October 30, 2026PDF · 17 pages
NVIDIA: AI platform economics, cash generation and contingent commitments
Examines NVIDIA as an integrated computing platform, connecting processors, networking, software and deployment capacity to customer utilization and economic returns. July revenue, operating cash, liquid assets, debt and capital allocation are considered alongside inventory, supplier reservations and packaging constraints. Customer concentration, export restrictions, equity commitments and conditional residual-value guarantees define risks that remain distinct from announced infrastructure capacity and product performance.
$RIGLResearch as of October 29, 2026PDF · 12 pages
Rigel: VEPPANU launch, commercial cash flow and R289
Examines VEPPANU's approved breast-cancer indication and commercial launch alongside TAVALISSE, REZLIDHIA and GAVRETO, distinguishing product demand from licensing economics. The financial chapters connect operating cash generation with the upfront investment, supply commitments, revolver repayment, equity incentives and dilution. Early R289 response evidence is considered with patient selection, durability and safety, showing how a commercial business and an investigational pipeline create different tests for future value.
$MSLEResearch as of October 21, 2026PDF · 14 pages
Satellos: BASECAMP evidence, muscle regeneration and funding
Explores forazapadin's muscle-regeneration rationale through the controlled pediatric BASECAMP study, four-adult TRAILHEAD observations and the planned FSHD program. Enrollment, delayed result guidance, biomarker changes and functional measures are separated from proof of clinical benefit. June cash and investment balances, rising development expenditure, conditional foundation funding, pre-funded warrants and the ATM program frame the financing and dilution risks surrounding the next clinical milestones.
$XRTXResearch as of October 10, 2026PDF · 14 pages
XORTX: XORLO evidence, regulatory plans and financing risk
Examines XORLO's formulation and pharmacokinetic history, the proposed XRx-026 gout study and the separate US IND and Canadian CTA pathways. The discussion distinguishes development preparation from authorization, clinical efficacy and a later funding-dependent NDA ambition. June cash, working capital, prepaid services and conflicting historical cash-flow presentations are assessed alongside offering proceeds, investor-relations commitments, pre-funded warrants, reverse splits and the larger economic share base behind the small common-share count.
$PRAXResearch as of October 27, 2026PDF · 17 pages
Praxis Precision Medicines: trial evidence, two FDA reviews and the launch transition
Relutrigine and ulixacaltamide are assessed through their different neurological indications, trial designs, regulatory histories and potential commercial requirements. The analysis examines Essential 3 attrition and tolerability, EMBOLD and EMERALD evidence, antisense development and the implications of the vormatrigine program setback. Historical cash, operating spending, launch preparation, warrants, awards and financing capacity frame the resources and dilution behind a transition toward possible first products.
$CTNMResearch as of October 29, 2026PDF · 18 pages
Contineum: PIPE-791 efficacy, LPA1 safety and the funding horizon
Examines PIPE-791’s receptor biology, early human observations and the controlled PROPEL-IPF design, while keeping the partnered PIPE-307 setbacks and competing LPA1 trials separate. Cash, securities, research spending and runway assumptions are assessed with share classes, ATM capacity, ownership and licensing economics. The report connects a concentrated clinical pipeline to liver-safety concerns, development timing and the limits of using historical liquidity as a valuation argument.
$LXRXResearch as of October 29, 2026PDF · 24 pages
Lexicon: sotagliflozin’s regulatory path, clinical tests and funding
Follows sotagliflozin through INPEFA commercialization, SONATA-HCM and the renewed ZYNQUISTA submission plan, keeping clinical endpoints, exposure requirements and DKA risk distinct. Novo-funded LX9851, international rights and pilavapadin add separate opportunities and partner dependencies. June liquidity, operating losses, Hercules financing, cash covenants, the ATM, concentrated ownership and a larger share base show how a stronger balance sheet still leaves execution and dilution risks. Update label: October 29; earlier review attribute: October 23.
$UNCYResearch as of October 21, 2026PDF · 15 pages
Unicycive: OLC vendor remediation, the FDA review and warrant claims
Follows OLC’s two complete response letters, second-vendor resubmission and accepted FDA review, separating manufacturing compliance from clinical tolerability and commercial adoption. The clinical discussion preserves the treated and evaluable populations behind phosphate-control and pill-burden claims. June cash, operating use, runway guidance, two securities actions, pre-funded instruments and milestone-linked warrant expirations show how regulatory progress interacts with funding needs and substantial potential dilution.
$QUREResearch as of October 28, 2026PDF · 18 pages
uniQure: AMT-130 evidence, regulatory strategy and gene-therapy resources
AMT-130 is examined through Huntington disease progression, external-control selection, durability, endpoint hierarchy and the difference between prespecified and exploratory results. The report follows the BLA strategy, safety questions, potential confirmatory evidence and the broader gene-therapy pipeline. Historical cash, operating spending, equity financing, share dilution and legacy HEMGENIX economics frame the resources behind development. The October 28 editorial attribute is distinct from the earlier visible review label and dated financial snapshots.
$WOLFResearch as of October 29, 2026PDF · 15 pages
Wolfspeed: financing conditions, silicon carbide economics and ownership risk
The analysis separates Wolfspeed’s conditional government loan commitment from funded cash, completed refinancing and product orders. It examines staged contributions, debt equitization, warrants and ownership after restructuring, then connects silicon carbide manufacturing, 200 mm substrates and customer qualifications with utilization, margins and cash generation. Historical results and prospective financing terms frame the commercial opportunity without treating technical progress or a facility ceiling as a valuation conclusion.
$FBIOResearch as of October 30, 2026PDF · 16 pages
Fortress Biotech: Emrosi growth, portfolio monetization and common-share claims
Explores Fortress as a pharmaceutical asset platform rather than a single-drug developer, connecting Emrosi commercialization with ZYCUBO voucher monetization, royalties and externally funded partner programs. Dotinurad, oncology interests and other development assets are considered alongside consolidated cash, operating losses and the Oaktree repayment. Subsidiary ownership, preferred dividends, warrants and capital allocation frame the central question of how portfolio progress reaches each Fortress common share.
$KRMNResearch as of October 28, 2026PDF · 15 pages
Karman: binding backlog, Walker integration and the conversion of growth into cash
Analyzes Karman’s space and defense components business through committed backlog, organic growth and the production rhythms of its end markets. Reported profit is compared with working capital, contract assets, capital spending and the stated second-half cash expectation. Walker integration, term-loan obligations, covenant conditions, capacity investment and ownership mechanics explain why a larger order book must ultimately produce collections and cash after financing costs.
$LFWDResearch as of October 27, 2026PDF · 14 pages
Lifeward: rehabilitation sales, working capital and convertible financing
Examines ReWalk and AlterG commercial recovery alongside reimbursement, distribution and the evidence supporting rehabilitation devices. June cash, operating consumption, receivables and purchase commitments show why revenue growth must translate into collections. The report unpacks secured notes, conditional capital, pre-funded securities, warrants and the shareholder vote on issuance limits, while separating the experimental oral-insulin program and longer-term product roadmap from the existing device business.
$NCLHResearch as of October 29, 2026PDF · 17 pages
Norwegian Cruise Line: yield, refinancing and the fleet funding burden
Examines Norwegian, Oceania and Regent as one capital-intensive cruise group, connecting capacity, occupancy and yields with quarterly operating results. September refinancing, the October notes closing and raised annual outlook are assessed against cash flow, debt service, liquidity and extensive ship commitments. Fleet additions, destination projects, fuel and geopolitical exposure frame the question of whether stronger revenue can support durable deleveraging after investment.
$IMVTResearch as of October 22, 2026PDF · 16 pages
Immunovant: FcRn evidence, RA trial design and licensed economics
Examines imeroprubart’s FcRn mechanism and the distinction between antibody reduction and disease-specific clinical benefit, including open-label rheumatoid-arthritis responses and the randomized maintenance test. The CLE failure, batoclimab discontinuation and competitor Sjogren setback frame the remaining Graves, myasthenia-gravis and later programs. June cash, operating spending, HanAll license obligations and Roivant control connect clinical opportunity with funding and per-share risk. Review label: October 22; market and assessment dates remain distinct.
$IONSResearch as of October 23, 2026PDF · 15 pages
Ionis: Hibsago royalties, commercial launches and financial claims
Connects Hibsago’s hepatitis-B evidence and approved population with GSK royalty terms, geographic rights and launch execution. Owned TRYNGOLZA, DAWNZERA and ZANVASTRO opportunities sit alongside European review, neurological and kidney programs, and the negative cardiovascular evidence. June revenue, cash consumption, convertible debt and royalty financing explain why approval and headline product sales differ from durable income retained by Ionis shareholders.
$ALMSResearch as of October 9, 2026PDF · 14 pages
Alumis: separate psoriasis and lupus evidence, resources and dilution
Envudeucitinib’s positive psoriasis studies are separated from the overall LUMUS lupus failure and its prespecified interferon-signature subgroup hypothesis. The report examines BICLA, endpoint hierarchy, subgroup denominators, safety and the regulatory requirements for an enriched development path. ONWARD durability, A-005, Kaken’s Japan rights, cash composition, operating use, equity financing and dilution connect the clinical evidence with the capital needed for potential filings, trials and commercialization.
$MTVAResearch as of October 28, 2026PDF · 14 pages
MetaVia: DA-1726 evidence, vanoglipel and the cost of reaching longer data
Examines DA-1726’s early weight-loss observations, the size and persistence of the treated cohorts, and the longer human-data windows needed to test the initial signal. Preclinical distribution findings and vanoglipel’s qualified liver-enzyme evidence are kept separate from confirmatory clinical outcomes. June cash, operating consumption, Dong-A payment obligations, completed financing, warrants, ATM capacity and incentives frame the resources and ownership cost of advancing the two development assets.
$TLXResearch as of October 29, 2026PDF · 18 pages
Telix: commercial imaging, the proposed ITM combination and regulatory execution
Connects Telix’s approved imaging franchise with its therapeutic pipeline, isotope supply and manufacturing strategy. Pixclara approval, the unresolved Zircaix manufacturing file and BiPASS development are analyzed as separate regulatory paths. Revenue growth and June cash flow are weighed against convertible debt, research spending and the proposed ITM combination, including share consideration, assumed debt, contingent milestones and closing conditions that determine the economics retained by existing holders.
$ZLABResearch as of October 23, 2026PDF · 15 pages
Zai Lab: regional rights, Zoci evidence and the limits of the cash headline
Examines Zai Lab’s regional medicines business alongside the global development opportunity in Zoci. Povetacicept and RAINIER evidence, territorial rights, early lung-cancer responses and the limitations of uncontrolled data are considered separately from established China sales and pricing pressure. June financial resources are decomposed into spendable investments, restricted cash and bank debt, with license costs, research spending, the ADS ratio and potential financing shaping retained value per share.
$DALResearch as of October 21, 2026PDF · 14 pages
Delta: premium travel, SkyMiles economics and cash after fleet spending
Examines Delta’s premium cabins, network and loyalty franchise through unit revenue, American Express remuneration and the planned Hyatt relationship. June accounts show how fuel costs and fleet spending can absorb commercial progress, while the September-quarter update revises the annual earnings and cash outlook. Debt maturities, aircraft commitments, international partnerships, labor obligations and shareholder distributions frame the cash required to turn service advantages into durable financial returns.
$APMDResearch as of October 12, 2026PDF · 17 pages
Apnimed: AD109 evidence, FDA meaningfulness and the cost of launch
Examines the completed SynAIRgy and LunAIRo trials through patient populations, airway measurements, estimands, reported symptoms and treatment persistence. FDA questions about clinical meaningfulness and adverse-event discontinuation frame the pending AD109 application, rather than an assumed approval. June cash, the subsequent IPO, conditional credit tranches, revenue participation, Shionogi economics and prospective dilution connect the oral-treatment opportunity with the resources and obligations needed for launch.
$ORICResearch as of October 28, 2026PDF · 18 pages
ORIC: enozertinib evidence, rinzimetostat validation and pivotal funding
Examines enozertinib through mutation groups, systemic and intracranial responses, patient denominators and the limits of early single-arm evidence. Rinzimetostat’s mechanism and Himalayas-1 randomized design are assessed separately from biomarker responses and competitor studies. June cash and investments, rising pivotal costs, licensed economics, manufacturing obligations and potential dilution connect the two oncology programs with the resources and evidence needed to reach a useful regulatory and commercial outcome.
$BBIOResearch as of October 29, 2026PDF · 44 pages
BridgeBio: Attruby revenue, three applications and senior capital claims
Attruby’s product revenue, partner royalties and license milestones are traced through quarterly accounts and the economics retained by BridgeBio and its subsidiaries. Three applications are examined alongside clinical denominators, registry distinctions and observational comparison limits. Convertible notes, program-level royalty sales, cumulative preferred equity, repurchases, ownership and potential dilution show how commercial progress interacts with senior claims. September-quarter updates are preserved beside earlier June detail, without presenting all figures as one reporting period.
$CRBPResearch as of October 23, 2026PDF · 15 pages
Corbus: ADC evidence, obesity tolerability and the financing path
CRB-701’s Nectin-4 ADC design is followed through indication-specific tumor responses, evaluable populations, ocular toxicity and the randomized TEMPO-1 strategy. CRB-913’s peripheral CB1 mechanism and CANYON-1 weight-loss signal are examined alongside psychiatric tolerability, dose exposure and chronic-treatment requirements. Licensing territories, milestones, royalties, historical cash use, financing capacity and potential dilution connect the two clinical programs with the resources and retained economics needed to reach larger studies.
$AIResearch as of October 15, 2026PDF · 14 pages
C3.ai: enterprise deployment, cash conversion, equity funding and voting control
Examines C3.ai’s enterprise software model and the difference between workshop activity, paid deployments and durable customer revenue. The July quarter is compared with the prior annual contraction, gross margins and the cash bridge created by operating activity and financing. Stock compensation, the proposed equity-plan decision, voting control, contractual obligations and litigation frame the capital allocation and execution risks surrounding a potential commercial recovery.
$CCLResearch as of October 23, 2026PDF · 15 pages
Carnival: cruise demand, fuel, cash generation and the debt reduction test
Follows Carnival’s bookings and passenger yields through operating costs, customer deposits, cash generation and ship investment. The August results separate stronger revenue from the financing effects on net income and examine fuel exposure, efficiency and the assumptions behind guidance. Debt maturities, unsecured refinancing, fleet additions, destinations, rewards accounting, buybacks and dividends show how operating improvement must support both investment and shareholder returns without obscuring the remaining financial obligations.
$DYNResearch as of October 29, 2026PDF · 16 pages
Dyne: FORCE delivery, DMD review, DM1 evidence and development financing
Examines Dyne’s FORCE delivery platform and the different evidentiary paths for exon-51 DMD and myotonic dystrophy. Biomarker findings, exploratory pooled observations, registrational data and confirmatory studies are kept distinct, with regulatory review separated from approval and commercial access. The report connects launch preparation and trial execution with June liquidity, July equity proceeds, debt conditions, spending and potential dilution, while testing the assumptions that support the funding horizon.
$ELTXResearch as of October 23, 2026PDF · 13 pages
Elicio: AMPLIFY evidence, lymph-node targeting and the financing of future studies
Separates the randomized AMPLIFY-7P primary-endpoint miss from immune responses, nominal subgroups and exploratory adjusted analyses. The report compares the 7P strategy with earlier AMPLIFY-201 observations and examines the requirements for prospective combinations or a refined development population. Intellectual property, manufacturing, secured obligations, June cash consumption, July financing and potential dilution determine the resources and ownership cost of advancing ELI-002 after the clinical setback.
$NKTRResearch as of October 27, 2026PDF · 14 pages
Nektar Therapeutics: REZPEG evidence, selected responders and pivotal funding
Compares randomized dermatitis evidence with the missed original alopecia primary analysis and later selected-responder durability data, emphasizing the five-of-eight denominator. The ZENITH development roadmap separates trial initiation, future pivotal results and a conditional filing path. June cash and investment categories, historical operating consumption, research prepayments, financing dilution and the uncollected Lilly verdict explain the resources and obligations behind a broader Phase 3 program without turning cash arithmetic into management guidance.
$AALResearch as of October 29, 2026PDF · 16 pages
American Airlines: network growth, fuel economics and balance-sheet limits
Examines American’s network and loyalty economics, premium cabins, the Alaska joint-business proposal and the separate STARLUX codeshare. June financial statements connect record revenue with fuel pressure, narrow margins, liquidity facilities, debt, aircraft commitments and equity capacity, while later dated news includes the third-quarter loss and Azul warrant investment. Scenarios distinguish stronger customer demand from sustainable cash generation and the regulatory and operating work required to turn partnerships into returns.
$REPLResearch as of October 29, 2026PDF · 19 pages
Replimune: TUDRIQEV approval, launch economics and confirmatory risk
Traces TUDRIQEV’s regulatory reversals through accelerated approval, the approved melanoma population, administration requirements and safety qualifications. IGNYTE response evidence is separated from the survival obligation in IGNYTE-3 and the earlier RP2 pipeline. September resources, launch cash consumption, the going-concern conclusion, Hercules covenant alternatives, equity financing and pre-funded warrants explain how regulatory progress can coexist with commercial, clinical and dilution risk.
$RXTResearch as of October 29, 2026PDF · 17 pages
Rackspace Technology: conditional AI deployment, cash conversion and debt
Examines Public and Private Cloud economics, the definitive AMD compute framework and its deployment-specific approvals, residual-capacity conditions and capital requirements. Palantir, NVIDIA and HGS announcements are separated from contracted revenue, utilization and realized returns. Final quarterly results, adjusted-profit reconciliations, operating cash use, debt principal versus carrying amounts, 2028 maturities, leases and ATM capacity frame whether the enterprise AI transition can improve common-shareholder economics.
$AGIOResearch as of October 30, 2026PDF · 17 pages
Agios Pharmaceuticals: mitapivat evidence, extended review and commercial economics
Examines mitapivat’s approved indications and pending sickle-cell pathway, separating the positive RISE UP hemoglobin response from the missed pain-crisis and fatigue outcomes. REIGNITE, surrogate reasoning, liver-safety monitoring, AQVESME’s REMS and the October review extension frame regulatory risk. Product-sales growth, nonrecurring acquired research expense, cash and investment categories, operating consumption, retained royalties and equity capacity connect the clinical strategy to commercial returns and financing requirements.
$ALLOResearch as of October 29, 2026PDF · 16 pages
Allogene Therapeutics: ALPHA3 evidence, safety history and cell-therapy funding
Separates ALPHA3’s small molecular interim groups from blinded survival endpoints, documenting the closed ALLO-647 arm, safety attribution and subsequent design changes. ALLO-329 and the broader pipeline retain their own evidence and development windows. June investment resources, cash-flow timing, state research funding, the April equity raise, shelf financing capacity, ownership denominators and leadership transitions connect clinical execution to runway and potential dilution without treating cash as a share-price floor.
$EDSAResearch as of October 16, 2026PDF · 17 pages
Edesa: EB06 trial design, inflammatory-disease evidence and financing
EB06’s anti-CXCL10 rationale is connected to the placebo-controlled vitiligo design, facial endpoint, recruitment sequence and limits of earlier exposure data. Paridiprubart respiratory results and exploratory kidney-injury analyses are distinguished from prospective confirmation, with daniluromer adding a separate development option. Historical cash, the August offering, warrants, licensing obligations and preferred instruments frame the funding and dilution needed to produce controlled evidence. Report label: October 16; an October 23 compensation update is preserved separately.
$IBIOResearch as of October 20, 2026PDF · 12 pages
iBio: obesity antibody translation, fiscal runway and pre-funded ownership
The report traces iBio’s obesity antibodies from target biology and animal body-composition observations to early human dosing and planned clinical windows. It distinguishes target inhibition, the composition of lost mass and potential patient benefit, while examining the different stages of IBIO-600, IBIO-610 and IBIO-800. Fiscal cash use, runway assumptions, licenses, ordinary and pre-funded warrants, incentive reserves and the completed October capital vote show how development progress interacts with ownership and financing.
$USARResearch as of October 12, 2026PDF · 15 pages
USA Rare Earth: integrated production, buyer funding and capital demands
The expanded rare-earth platform is followed from Serra Verde and Less Common Metals to Stillwater magnets, Round Top and planned processing capacity. Production targets, customer qualification, buyer funding and cash collection are treated as separate operating tests. Historical cash, acquisition consideration, construction spending, conditional public support, offtake arrangements, warrants and resale restrictions show why industrial scale and strategic importance must still translate into workable economics for each common share.
$VRTXResearch as of October 23, 2026PDF · 17 pages
Vertex: renal evidence, Crinetics integration and the commercial cash engine
Vertex’s cystic-fibrosis cash engine is evaluated beside pain, cell-therapy and kidney development, with particular attention to povetacicept’s accelerated-review pathway and inaxaplin’s evidence limits. The completed Crinetics acquisition adds endocrine commercialization and integration questions. Pre-close financial resources, loan facilities, launch models, management peak-sales estimates and post-deal accounting show how clinical diversification must produce durable returns rather than merely a broader portfolio.
$ARCTResearch as of October 26, 2026PDF · 11 pages
Arcturus: OTC delivery, CF development and cash commitments
The September OTC results are examined through the small efficacy and safety populations, liver tolerability and the proposed transition to LUNAR 2.0. Cystic-fibrosis imaging and longer treatment, manufacturing services and the myNEO agreement add separate execution requirements. June cash, operating use, released CSL obligations, equity capacity and ownership explain the resources and commitments behind the next development cycle. The October 26 report label is distinct from the earlier visible news label.
$CLDXResearch as of October 2, 2026PDF · 17 pages
Celldex: CSU response, pivotal safety and the capital path to filing
Barzolvolimab’s two pivotal CSU trials are analyzed through response denominators, durability and the detailed adverse-event tables, including anaphylaxis, neutropenia and hair-color changes. Earlier off-treatment follow-up and the different prurigo-nodularis outcome frame the limits of the mast-cell hypothesis. June resources, equity funding, unused ATM capacity, ownership and the approval-contingent Kolltan settlement show the capital requirements behind a planned BLA and broader immunology development.
$MBRXResearch as of October 22, 2026PDF · 15 pages
Moleculin: MIRACLE interpretation, financing and the post-split capital structure
MIRACLE’s first randomized unblinding, prior-treatment subgroups and cardiac-safety observations are examined without substituting blinded updates for the complete analysis. Trial design and dose selection frame the Annamycin program alongside the broader pipeline. The completed August financing, warrants, ATM use, dated cash-flow bridge and October reverse split show the funding trade-offs, while listing uncertainty and trial execution remain explicit risks.
$RLAYResearch as of October 28, 2026PDF · 14 pages
Relay: zovegalisib selectivity, vascular evidence and the trial-funding bridge
Zovegalisib’s mutant-selective design is examined through ReDiscover-2, the Phase 3 dose, frontline triplet observations and early vascular-anomaly data, with separate cutoffs and response denominators. Pfizer’s supply agreement is distinguished from Relay’s retained rights and trial costs. June liquidity, historical cash use, the May equity offering and contingent future spending connect the clinical evidence requirements with the per-share funding case.
$INCYResearch as of October 29, 2026PDF · 18 pages
Incyte: Jakafi exposure, commercial diversification and acquisition economics
Connects Jakafi’s expected exclusivity loss with Opzelura, hematology and oncology launches, late-stage development and the economics of acquiring replacement growth. September results separate stronger sales from the Vega IPR&D charge, while earlier June comparisons retain their own periods and CMS-related accounting effects. Regulatory windows, early oncology evidence, cash resources, voting and ownership, competitive pressure and capital allocation frame the effort to sustain earnings beyond the largest product. Date label: October 29; includes October 30 updates.
$LRMRResearch as of October 17, 2026PDF · 15 pages
Larimar: frataxin replacement, surrogate approval and the cost of confirmation
Examines nomlabofusp’s mitochondrial protein-replacement thesis and the use of skin frataxin as a proposed surrogate for accelerated approval. Open-label biomarker and functional groups, external natural-history comparisons, exposure and anaphylaxis are assessed separately from randomized confirmation. The rolling application, manufacturing and registry timelines are connected to launch preparation, cash runway, preferred conversion, options and the potential financing needed beyond the initial regulatory window.
$STIMResearch as of October 21, 2026PDF · 18 pages
Neuronetics: device and clinic economics, cash restrictions and the covenant test
Traces NeuroStar’s device and recurring treatment revenue alongside Greenbrook’s clinic network and the operating changes behind the June-quarter margin improvement. Positive adjusted EBITDA is separated from GAAP losses, interest expense and unrestricted cash. Reimbursement, practice integration and patient access are connected to debt covenants, the projected March 2027 shortfall, ATM issuance, warrants, concentrated ownership and the shareholder framework that shapes governance and financial execution.
$OGNResearch as of October 30, 2026PDF · 15 pages
Organon: transaction conditions, women’s health products and debt economics
Examines the Sun Pharma agreement alongside the operating business that remains if closing is delayed: Nexplanon, MIUDELLA, VTAMA, biosimilars and established brands. The report separates regulatory review, single-arm clinical observations and launch preparation from completed approvals. June operating cash generation, JADA divestiture proceeds, borrowings, distributions, governance and product replacement are connected to the conditions and financial consequences of the proposed cash acquisition.
$UBERResearch as of October 29, 2026PDF · 14 pages
Uber: marketplace economics, cash-flow boundaries and the cost of expansion
Examines how Mobility, Delivery and Freight convert marketplace activity into recognized revenue, operating earnings and cash. The report separates investment gains, stock compensation, insurance reserves and restricted collateral from the resources available for capital allocation. Delivery Hero conditions, ezCater and other acquisitions, autonomous partnerships, debt refinancing, exchangeable instruments and repurchases show how network expansion can change financing needs and retained value even while operating cash generation improves.
$ORKAResearch as of October 27, 2026PDF · 17 pages
Oruka: controlled psoriasis evidence, durability and common-equivalent dilution
Follows ORKA-001 from early dosing through EVERLAST-A and the randomized EVERLAST-B Week 16 results, distinguishing within-study evidence from cross-trial comparisons. Durability, dose selection, safety and competition frame the potential advantage of longer treatment intervals. ORKA-002, hidradenitis suppurativa and earlier optionality are assessed separately, while licensing, manufacturing, June liquidity, July financing, preferred conversion, pre-funded warrants and employee awards determine the resources and ownership cost of pivotal development.
$ARQTResearch as of October 28, 2026PDF · 16 pages
Arcutis: ZORYVE growth, indication expansion and the operating leverage test
Analyzes ZORYVE as one molecule across formulations and dermatology indications, with commercial growth separated from pending infant review and exploratory development in vitiligo and hidradenitis suppurativa. The report follows patient access, pricing deductions, distribution and the internal sales-force transition through June product sales, profitability and cash generation. Debt, dilution, concentration, competition and the cost of expanding the franchise frame whether quarterly operating progress can become durable shareholder economics.
$NNVCResearch as of October 22, 2026PDF · 18 pages
NanoViricides: antiviral evidence, program rights and financial continuity
NV-387’s Ebola exploratory run-in and planned controlled stage are distinguished from the separate mpox program and animal toxicology. Study design, dosing, safety interpretation and regulatory designations frame what patient evidence must establish. The fiscal-year cash bridge, subsequent financing, related-party credit, program rights, warrants and ATM restrictions explain why clinical progress and financial continuity must be evaluated together rather than treating permission or capacity as efficacy or cash.
$OSCRResearch as of October 20, 2026PDF · 13 pages
Oscar Health: insurance margins, enrollment quality and parent capital
Oscar’s ACA insurance economics are examined through premium pricing, medical-loss ratios, reserve development and full-year profitability rather than enrollment alone. The September outlook and 2027 product lineup sit beside CMS eligibility enforcement and parent-capital constraints. June consolidated cash, settlement payables, unpaid benefits, operating cash timing, convertible debt and existing-share distributions explain why a large group balance does not automatically provide equivalent shareholder flexibility.
$RZLTResearch as of October 30, 2026PDF · 17 pages
Rezolute: ersodetug evidence, separate HI indications and funding
Examines ersodetug’s insulin-receptor mechanism across congenital and tumor-associated hyperinsulinism, preserving sunRIZE’s failed prespecified endpoints alongside the small, uncontrolled upLIFT evidence. FDA pre-BLA dialogue, mid-December topline guidance and the later filing plan are separated from approval. June resources, annual cash consumption, pre-funded warrants, share authorization and contingent license milestones frame the funding and retained economics. Latest written revision: October 30; the header retains October 10.
$BFRIResearch as of October 8, 2026PDF · 14 pages
Biofrontera: Ameluz label expansion, treatment economics and capital needs
Examines Ameluz’s drug-and-lamp photodynamic therapy platform, the approved superficial basal-cell indication and the separate submitted actinic-keratosis expansion. The planned launch window is weighed against reimbursement, adoption, lamp supply, legal and patent conditions and orders brought forward before potential restrictions. Revenue growth and gross-margin improvement are separated from operating losses, limited cash, going-concern doubt, expected milestones and share dilution, preserving the dates of each commercial and financial claim. Latest written news review: October 8.
$MEDSResearch as of October 26, 2026PDF · 15 pages
DataMeds AI: pharmacy operations, capital repair and control dilution
DataMeds’ pharmacy rebuild and oncology-laboratory acquisition are assessed against June losses, working-capital pressure and the difference between accounting equity repairs and operating cash. The report follows Helomics, ChemoFx coverage limits, REBOOT licensing and the revised control-transaction framework. Convertible-note formulas, preferred-conversion steps, warrants, resale registration and proposed ownership allocations show how business growth can coexist with substantial dilution and continuing listing requirements.
$URGNResearch as of October 28, 2026PDF · 14 pages
UroGen: commercial growth, collections and financing
Archived analysis of ZUSDURI and JELMYTO commercial adoption, clinical response evidence and the UGN-103 development pathway. It examines first-half cash use, receivables, the Pharmakon loan and RTW revenue-linked payments, then sets out scenarios and evidence that could challenge the assessment.
$HIMSResearch as of October 28, 2026PDF · 16 pages
Hims & Hers: growth quality, Eucalyptus and financial obligations
This dated report examines the second-quarter revenue mix, margin decline and cash conversion as branded weight-loss medicines and Eucalyptus enter the business. It details acquisition accounting and future payments, convertible notes, working capital, legal exposure and the governance structure, with scenarios and financial benchmarks for later results.
$QTTBResearch as of October 12, 2026PDF · 18 pages
Q32 Bio: SIGNAL-AA evidence, pivotal plans and financing
The archive explains SIGNAL-AA Part B response rates, the mITT and ITT denominators and the selected off-drug follow-up cohort presented at EADV. It examines bempikibart biology, competition, the proposed pivotal pathway, June cash and July financing, together with pre-funded warrants, dilution scenarios and the remaining evidence gaps.
$TVTXResearch as of October 26, 2026PDF · 16 pages
Travere Therapeutics: FILSPARI, kidney disease and capital allocation
The archived report examines FILSPARI in IgA nephropathy and the approved FSGS population, including label limits, launch evidence and revenue quality. It follows the Q2 operating bridge, convertible notes, civorebrutinib, pegtibatinase and the evidence that would strengthen or weaken the commercial case.
$BCTXResearch as of October 28, 2026PDF · 16 pages
BriaCell: Bria-IMT, the survival trial and financing constraints
Archived analysis of Bria-IMT, the randomized Bria-ABC survival study and the distinction between DSMB monitoring, early clinical observations and an efficacy readout. It covers manufacturing arrangements, the wider cell-therapy pipeline, cash consumption, financing and dilution. The original report retains its April and July financial references and the October annual-filing update.
$LGVNResearch as of October 28, 2026PDF · 17 pages
Longeveron: laromestrocel after ELPIS II and the financing test
Archived research on the ELPIS II primary endpoint miss, subsequent cardiac-event analyses and the separate frailty and Alzheimer’s programs. The report examines strategic alternatives, June liquidity, preferred-stock conversion exposure and the financing conditions tied to clinical progress. It preserves the differing dates and denominators of the September and October disclosures.
$UECResearch as of October 12, 2026PDF · 14 pages
Uranium Energy: production ramp, cash conversion and equity funding
The archived report distinguishes mined pounds, purchased uranium inventory, customer sales and cash receipts at Christensen Ranch and Burke Hollow. It examines fiscal 2026 cash consumption, equity financing, dilution and the permitting and budget steps still facing Sweetwater and the proposed conversion business.
$TNGXResearch as of October 23, 2026PDF · 17 pages
Tango Therapeutics: PRMT5, pancreatic cancer and the development test
Archived research on the MTAP-deletion rationale, vopimetostat monotherapy and the early RAS-combination cohorts, with attention to evaluable-patient denominators, safety and durability. The report examines the randomized-development path, June financial resources, capital structure and the economics of partner-dependent combinations. Original clinical and market reference dates are retained.
$MARResearch as of October 21, 2026PDF · 14 pages
Marriott: hotel fees, debt, room growth and shareholder distributions
The archived report traces Marriott’s franchise and management fees from hotel demand to cash available for investment and capital returns. It examines June-quarter results, regional demand, room openings, Bonvoy and credit cards, the September refinancing and why buybacks can exceed operating cash generation.
$ASPIArchive captured October 31, 2026PDF · 19 pages
ASP Isotopes: production milestones and capital claims
The archive follows isotope enrichment, helium commissioning and the proposed Noble Africa transaction across ASPI’s corporate structure. It separates consolidated cash, project spending and convertible claims from commercial deliveries, customer qualification and the longer-term ambitions of Quantum Leap Energy. The original research revision date is not stated; this archive copy was captured on October 31, 2026.
$BATLArchive captured October 31, 2026PDF · 16 pages
Battalion Oil: production, debt and preferred capital
The report examines the Delaware Basin production base, realized pricing and the development plan under JEDA. Cash and restricted balances are assessed alongside term-loan amortization, preferred-stock claims and common-share dilution, with scenarios for how operating improvements could reach shareholders. The original research revision date is not stated; this archive copy was captured on October 31, 2026.
$AKBAArchive captured October 31, 2026PDF · 17 pages
Akebia: Vafseo, VOICE and the franchise transition
This report connects Vafseo’s commercial ramp with Auryxia pressure and the evidence from the VOICE study. It explains the distinction between hospitalizations and mortality, approved dosing and trial dosing, then examines refinancing, cash requirements and the Phase 2 rare-disease portfolio. The original research revision date is not stated; this archive copy was captured on October 31, 2026.
$TRAWArchive captured October 31, 2026PDF · 17 pages
Traws Pharma: antiviral evidence, holds and funding
This archive traces tivoxavir and ratutrelvir through clinical evidence, regulatory setbacks and the limits of early antiviral results. It examines the financing triggers, warrants, Nasdaq requirements and legacy oncology assets that make permission to study, interpretable data and available capital interdependent. The original research revision date is not stated; this archive copy was captured on October 31, 2026.
$FJETArchive captured October 31, 2026PDF · 17 pages
Starfighters Space: starlaunch and flight testing
The report examines how the F-104 fleet supports airborne testing and the staged STARLAUNCH development program, distinguishing hardware, captive carry and later powered flight. It follows cash consumption, restricted resources, warrants, governance disputes and the need for repeat customer-funded missions. Original research revision date not stated; this archive copy was captured October 31, 2026.
$UAVSArchive captured October 31, 2026PDF · 17 pages
AgEagle Aerial Systems (EagleNXT): drones and aerial sensors
The report examines the eBee drone and MicaSense sensor businesses, domestic manufacturing, anti-jamming development and the ThirdEye counter-UAS expansion. It separates shipments and procurement eligibility from profitable sales, then traces cash use, preferred securities and dilution through the legal AgEagle issuer. Original research revision date not stated; this archive copy was captured October 31, 2026.
$CLGNResearch as of October 30, 2026PDF · 21 pages
CollPlant and LightSolver: photonic computing, rhCollagen and funding
The archived report explains LightSolver’s laser-based computing architecture, the HLRS projected benchmark and the limits of translating emulator results to deployed hardware. It also examines Boeing and defense development work, CollPlant’s rhCollagen programs, historical cash use, acquisition consideration and conditional dilution.
$ADCTResearch as of October 29, 2026PDF · 14 pages
ADC Therapeutics: ZYNLONTA, LOTIS evidence and restructuring
The archive examines the benefit-risk questions from LOTIS-5 and the evidence still required from LOTIS-7 and marginal-zone lymphoma development. It explains the conditional PIPE, loan and royalty amendments, then separates the Japanese filing and commercialization arrangements from an approval or guaranteed cash receipt.
$BDRXResearch as of October 26, 2026PDF · 12 pages
Biodexa: Serenta, bladder-cancer evidence and financing pressure
The archived research examines Serenta’s event-driven FAP study, the fully enrolled bladder-cancer trial and the limits of earlier efficacy observations. It separates sterling cash and operating consumption from dollar financing proceeds, and explains warrant terms, resale registration and the announced ADS-ratio change.
$CANFResearch as of October 4, 2026PDF · 18 pages
Can-Fite BioPharma: namodenoson and piclidenoson
The report examines the blinded LIVERATION survival observation, the pivotal psoriasis program and the exploratory pancreatic-cancer evidence without combining their different designs. It follows the A3 adenosine-receptor platform, June financial resources, September warrant financing and the potential ownership changes from repeated funding.
$OPTTResearch as of October 29, 2026PDF · 18 pages
Ocean Power: maritime systems and financing constraints
The report follows PowerBuoy and WAM-V from customer evaluations and maritime missions to backlog conversion. It examines gross losses, quarterly cash use, convertible-note exchanges, the proposed offering and shareholder approvals, distinguishing framework ceilings and operational selections from funded revenue.
$ZYMEArchive captured October 31, 2026PDF · 19 pages
Zymeworks: Ziihera economics, Theravance and the owned pipeline
This research separates Ziihera milestone and royalty economics from the Theravance acquisition and YUPELRI collaboration revenue. It examines acquisition financing, capital allocation, the HERIZON-GEA-01 evidence, ZW191 dose optimization and the October Roche license for ZW209, preserving the original reference dates. Original research revision date not stated; archive copy captured October 31, 2026.
$QCLSResearch as of October 13, 2026PDF · 15 pages
Q/C Technologies: optical computing and capital
The report explains the optical processing-unit initiative, the Sandia research relationship and the technical evidence needed to connect architecture to a useful workload. It follows the termination of the earlier LightSolver license, historical cash and securities, preferred instruments and the economic claim left to common shareholders.
$TARAArchive captured October 31, 2026PDF · 16 pages
Protara: TARA-002, IV Choline Chloride and development economics
Research covering the bladder-cancer and lymphatic-malformation evidence for TARA-002 and the separate replacement-biology rationale behind IV Choline Chloride. It examines THRIVE-3 enrollment, response denominators, regulatory and manufacturing tasks, June resources and spending across the pipeline. Original research revision date not stated; archive copy captured October 31, 2026.
$MNTSArchive captured October 31, 2026PDF · 16 pages
Momentus: vigoride and orbital services
The report examines Vigoride mission execution, the proximity-operations demonstration, NASA formulation work and the economics of hosted payloads. It distinguishes preparatory contracts from flight awards and follows the June cash reserve, operating consumption, financing inflows and the demands of repeat missions. Original research revision date not stated; this archive copy was captured October 31, 2026.
$CRDLArchive captured October 31, 2026PDF · 17 pages
Cardiol Therapeutics: cardiolrx and maveric
The report examines CardiolRx in recurrent pericarditis, the uncontrolled pilot evidence, the expanded pivotal MAVERIC trial and the separate ARCHER myocarditis program. It distinguishes blinded event observations from efficacy, and follows Canadian-dollar financial statements, subsequent U.S.-dollar financing and the assumptions behind runway guidance. Original research revision date not stated; this archive copy was captured October 31, 2026.
$HLTResearch as of October 29, 2026PDF · 15 pages
Hilton: hotel fees, demand and capital returns
Hilton’s franchise model is examined through fee generation, room growth and the cash available after investment. The archive connects dated financial results and the updated outlook with debt, incentive compensation, shareholder returns and the announced exchange transfer.
$MLYSResearch as of October 29, 2026PDF · 15 pages
Mineralys: lorundrostat evidence, regulatory review and economic rights
Archived research on the Launch-HTN and Advance-HTN blood-pressure evidence, safety, kidney-disease analyses and the December FDA target. It examines June cash and operating use, the debt facility, competitive positioning and the October termination of the Tanabe license with retained milestone obligations.
$QNTMResearch as of October 12, 2026PDF · 15 pages
Quantum BioPharma: Lucid-MS, Unbuzzd and capital allocation
This report separates Lucid-MS clinical clearance from proof of efficacy and Unbuzzd’s proposed listing from a completed transaction. It examines cash, digital assets, ownership and financing alongside litigation, spending and the evidence needed to sustain development.
$VTVTResearch as of October 27, 2026PDF · 17 pages
vTv Therapeutics: cadisegliatin evidence, CATT1 and per-share economics
Archived analysis of cadisegliatin’s mechanism, the earlier randomized and insulin-withdrawal studies, the CATT1 design and its distinct hybrid closed-loop pilot. It examines licensing accounting, normalized historical cash use, pre-funded warrants, territorial rights and the difference between enrollment and pivotal efficacy evidence.
$AMBAResearch as of October 16, 2026PDF · 16 pages
Ambarella: edge ai and cash conversion
The report examines CVflow processors, automotive and security demand, Oculii radar perception and the X7 route into existing host systems. It distinguishes distribution and software partnerships from contracted chip volumes, then follows the fiscal-2027 earnings bridge, cash conversion, stock compensation and manufacturing dependencies.
$NVCRResearch as of October 29, 2026PDF · 15 pages
Novocure: Tumor Treating Fields and commercial expansion
The archive follows Tumor Treating Fields across established indications and proposed new markets. It examines revenue quality, adoption, reimbursement, clinical endpoints and operating costs, with financial resources and regulatory pathways kept separate from commercial success.
$NYXHResearch as of October 27, 2026PDF · 12 pages
Nyxoah: Genio evidence, U.S. launch and euro financing
Research on the Genio neuromodulation system, DREAM, ACCCESS and BREATHE evidence, and the path from clinical outcomes to commercial implant activity. It examines reduced revenue guidance, euro cash consumption, debt and convertible obligations, dilution and the pending CCC indication-expansion supplement.
$RCLResearch as of October 29, 2026PDF · 14 pages
Royal Caribbean: cruise demand and sandals
The report follows the cruise business from bookings and customer deposits to ship investment, financing obligations and cash remaining for shareholders. It examines the conditional Sandals and Beaches investment, destination expansion, debt and capital returns, preserving June detailed analysis alongside the later third-quarter update.
$SCYXResearch as of October 22, 2026PDF · 18 pages
SCYNEXIS: antifungal development and contingent funding
SCY-247’s oral and intravenous development is assessed alongside healthy-volunteer evidence and the next clinical steps. The report explains the BARDA base period and optional funding, BREXAFEMME economics, cash use and dilution, distinguishing committed work from milestones that remain conditional.
$VIRResearch as of October 28, 2026PDF · 17 pages
Vir Biotechnology: hepatitis delta, PRO-XTEN and partnership economics
Archived research on the SOLSTICE evidence and the distinct ECLIPSE 1, 2 and 3 studies, followed by Vir’s PRO-XTEN oncology programs and partner-rights map. It examines Gilead, Astellas, Norgine, Sanofi and Alnylam economics, the composition of June liquidity, collaboration-related cash flow and share dilution.
$VORResearch as of October 30, 2026PDF · 16 pages
Vor Biopharma: telitacicept and global development
The report examines Vor’s transition toward telitacicept, including the different autoimmune indications and the global Phase 3 development path. It separates published clinical evidence, future regulatory work and licensing economics, with attention to financing, prefunded warrants and the common-share claim.
$VSTMResearch as of October 29, 2026PDF · 18 pages
Verastem: KRAS evidence, commercial launch and financing
The archive examines VS-7375 response denominators, confirmation status and the limitations of early oncology cohorts. It connects the approved low-grade serous ovarian cancer co-pack, the Novocure collaboration, financing and revenue-linked obligations with the next clinical and commercial evidence.
$ABUSResearch as of October 23, 2026PDF · 17 pages
Arbutus: HBV development, settlement economics and the tender
The archived report separates AB-101 and imdusiran clinical development from intellectual-property recoveries and Genevant economics. It traces the Moderna settlement receipt, conditional litigation paths, the completed 46 million-share tender, June cash flow and the gap before a reported post-tender balance sheet.
$ACIUResearch as of October 2, 2026PDF · 21 pages
AC Immune: vaccines and neurology
The report examines AC Immune’s active-immunotherapy platform and the clinical evidence in Parkinson’s and Alzheimer’s disease. It distinguishes biomarker and clinical endpoints, follows partner-dependent development milestones and analyzes Swiss-franc financial resources, milestone payments and runway assumptions.
$AIROResearch as of October 29, 2026PDF · 17 pages
AIRO: drones, contracts and cash conversion
This report follows AIRO’s aerospace businesses through drone demand, manufacturing and procurement pathways. It distinguishes potential framework access from awarded revenue and evaluates cash estimates, working capital, financing, operating performance and execution risk across the group.
$ALNYResearch as of October 30, 2026PDF · 16 pages
Alnylam: commercial RNAi, Huntington’s evidence and financing obligations
Archived research on the AMVUTTRA-led commercial franchise and the limits of initial brezosiran Huntington’s biomarker evidence. It examines HELIOS-B, the broader RNAi pipeline, partnership rights, revenue reconciliation, financing liabilities and the July guidance reduction alongside the reported third-quarter accounts.
$AMLXResearch as of October 16, 2026PDF · 22 pages
Amylyx Pharmaceuticals: avexitide and clinical development
The report examines Amylyx’s clinical programs, the avexitide development opportunity and the evidence needed to distinguish mechanism from patient benefit. It follows the relevant trial populations, regulatory steps, financial resources and financing sensitivities while preserving the original study and market dates.
$AMRXResearch as of October 30, 2026PDF · 17 pages
Amneal: complex medicines, earnings and financial claims
The archive examines Amneal’s complex injectable and specialty product mix, including the commercial implications of new approvals. It connects earnings, gross-to-net economics, debt and cash conversion with manufacturing, competition and the distinction between regulatory progress and durable shareholder returns.
$ANABResearch as of October 21, 2026PDF · 15 pages
AnaptysBio: retained royalties, Sagard thresholds and partner dependence
Research on the royalty company after the First Tracks separation, with a detailed distinction between retained Quimilza royalties and transferred milestone rights. It examines Jemperli clinical expansion, contractual litigation, Sagard receipt thresholds, the GEMINI evidence and the difference between tax-driven accounting profit and distributable cash.
$ANLResearch as of October 27, 2026PDF · 14 pages
Adlai Nortye: cancer pipeline and financing
The report examines Adlai Nortye’s oncology platform, the evidence for its clinical candidates and the limits of extrapolating early or combination data. It follows development milestones, licensing commitments, financial resources and the dilution and execution risks behind the pipeline.
$ARTLResearch as of October 29, 2026PDF · 12 pages
Artelo: early clinical evidence and financing risk
The report separates Artelo’s human pain-development programs from preclinical obesity observations and patent filings. It examines clinical design, potential differentiation, cash consumption, reverse-split mechanics and warrants, with scenarios tied to evidence rather than promotional comparisons.
$ATTOResearch as of October 2, 2026PDF · 11 pages
Attovia: chronic-pruritus evidence, ATTO-2306 and IPO funding
Archived research separates healthy-volunteer findings from initial chronic-pruritus patient observations and the planned complete Phase 1 b dataset. It examines ATTO-1310 and ATTO-2306, the competitive immunology setting, June cash use, the completed August IPO, option dilution and the planned transition to Phase 2.
$AVTXResearch as of October 30, 2026PDF · 15 pages
Avalo Therapeutics: abdakibart and clinical development
The report examines Avalo’s autoimmune-development strategy, the abdakibart program and the difference between early clinical evidence and a registration path. It follows trial design and milestones alongside cash consumption, financing securities and the dilution that can accompany further development.
$BKYIResearch as of October 29, 2026PDF · 14 pages
BIO-key: identity security, liquidity and dilution
The archive examines biometric authentication, customer adoption and the economics of BIO-key’s software and services. It sets operating losses and cash requirements against financing, warrant exposure and Nasdaq requirements, explaining why a customer announcement alone does not resolve the capital constraints.
$BLLNResearch as of October 24, 2026PDF · 14 pages
BillionToOne: prenatal screening, Northstar and laboratory economics
Research on UNITY prenatal screening and the growing Northstar oncology franchise, with the limits of prospective prenatal evidence and ctDNA assay concordance. It examines reimbursement and collection estimates, test volume, operating profitability, non-GAAP cash flow, debt valuation, dual-class ownership and financial-control risks.
$BLSMResearch as of October 23, 2026PDF · 15 pages
BlossomHill Therapeutics: precision oncology and pipeline
The report examines BlossomHill’s precision-oncology candidates, target selection and the clinical evidence needed to establish a useful treatment profile. It follows the post-IPO capital structure, June financial statements, development expenditure and the uncertainty between early programs and a commercial franchise.
$BLTEResearch as of October 19, 2026PDF · 14 pages
Belite Bio: retinal evidence, trial design and funding
This report explains the retinal-disease development program, its clinical endpoints and the distinction between interim evidence and a registrational outcome. Financial resources, spending, competitive approaches and potential dilution are considered alongside the milestones that would change the evidence base.
$BSINResearch as of October 13, 2026PDF · 17 pages
Big Sky Industrial: helium contract, carbon eligibility and project funding
The archived report follows Big Sky Industrial’s transition from legacy oil production to industrial gases and carbon management. It examines the signed helium agreement’s volume and commencement conditions, MRV and 45Q requirements, plant commissioning, credit-facility pricing and the capital needed before first commercial revenue.
$BTSGResearch as of October 30, 2026PDF · 15 pages
BrightSpring Health Services: care services and cash flow
The report examines BrightSpring’s pharmacy and provider-services model, demand drivers and the quality of reported growth. It follows margins, acquisitions, operating cash generation, debt and shareholder economics, with the original financial periods retained alongside the later quarterly update.
$CAEResearch as of October 26, 2026PDF · 15 pages
CAE: training demand, defense execution and cash
The archive examines civil aviation training and defense simulation through demand, backlog and contract execution. It connects Canadian-dollar financial statements with free cash flow, restructuring, debt and capital allocation, explaining the operational conditions behind management’s outlook.
$CARResearch as of October 30, 2026PDF · 15 pages
Avis Budget: fleet returns, ABS funding and cash after reinvestment
Archived analysis of rental pricing, utilization and residual-value assumptions across the Avis and Budget fleet. It distinguishes operating cash from vehicle renewal, corporate debt from fleet ABS, and consolidated earnings from shareholder economics, while tracing the Pentwater settlement, seasonal capacity reductions and the Waymo operating relationship.
$CBIOResearch as of October 30, 2026PDF · 17 pages
Crescent Biopharma: oncology pipeline and funding
The report examines Crescent’s oncology-development strategy, its principal clinical programs and the evidence expected from the next studies. It follows the rights and partnership structure, historical financial resources, cash consumption and potential dilution rather than treating a broad cancer market as established revenue.
$CERTResearch as of October 26, 2026PDF · 14 pages
Certara: retained operations, accounting and cash flow
This report examines Certara’s scientific software and technology-enabled services after the sale of Regulatory and Medical Writing. It separates continuing operations from consolidated losses and connects customer demand, repurchases, cash generation and organizational execution with the retained business.
$CGEMResearch as of October 19, 2026PDF · 18 pages
Cullinan: autoimmune T-cell engagers, zipalertinib and conditional economics
Research distinguishes the early autoimmune evidence for CLN-978 and velinotamig from CLN-049 leukemia development and zipalertinib’s regulatory applications. It examines dose and safety limits, the REZILIENT3 comparison, Taiho partnership economics, June liquidity, dilution and the separate November, December and FDA decision windows.
$CLYMResearch as of October 30, 2026PDF · 14 pages
Climb Bio: clym116 and budoprutug
The report examines CLYM116 and budoprutug across their distinct renal-immunology mechanisms, studies and patient populations. It preserves the preliminary Kidney Week findings and trial windows, then follows the April financing, June financial resources, cash consumption and clinical-safety risks.
$DCOYResearch as of October 20, 2026PDF · 16 pages
Decoy: designable antivirals, restricted cash and the warrant stack
The archived report examines peptide-based antiviral design, tissue-exposure findings and the difference between cell or animal observations and human efficacy. It follows the proposed Animal Rule route, respiratory development, restricted grant cash, September warrant inducement, the resale registration and financing needs before planned clinical entry.
$DMACResearch as of October 22, 2026PDF · 14 pages
DiaMedica Therapeutics: dm199 and clinical development
The report examines DM199, its proposed biology and the clinical evidence in vascular and neurological indications. It distinguishes trial milestones from treatment benefit, and follows manufacturing, regulatory execution, historical cash resources and the assumptions behind further funding needs.
$NAKArchive captured October 31, 2026PDF · 15 pages
Northern Dynasty: Pebble legal route, royalty economics and funding
Archived research follows the undeveloped Pebble resource through EPA restrictions, litigation, permitting, engineering and construction conditions. It distinguishes mineral resources from production, corporate cash from restricted balances, convertible principal from derivative fair value and the royalty burden from the company’s retained future economics. Original research revision date not stated; archive copy captured October 31, 2026.
$COGTResearch as of October 9, 2026PDF · 14 pages
Cogent: bezuclastinib, regulatory steps and resources
The archive follows bezuclastinib across clinical populations and regulatory milestones, with attention to study design and safety. It assesses cash, spending, capital structure and commercialization requirements while distinguishing strong trial results from completed approval or future sales.
$DRMAResearch as of October 29, 2026PDF · 13 pages
Dermata: Tome consumer demand, cosmetic evidence and financing
Archived analysis of the shift from the former prescription program to Tome skincare and the economics required after commercial availability. It examines the small open-label cosmetic study, the new acne-study design, retail pricing, June cash use, August financing, warrant conditions and resale-share supply.
$EPRXResearch as of October 24, 2026PDF · 18 pages
Eupraxia Pharmaceuticals: drug delivery and clinical data
The report examines Eupraxia’s drug-delivery platform, its clinical programs and the evidence needed to establish a durable therapeutic advantage. It follows study design, safety and regulatory milestones alongside June liquidity, cash use and the funding implications of later development.
$EWTXArchive captured October 31, 2026PDF · 16 pages
Edgewise: owned cardiac programs and retained Servier milestone exposure
The archived report separates owned EDG-7500 and EDG-15400 development from the muscular-dystrophy business sold to Servier. It examines CIRRUS-HCM’s open-label design and safety, the EQUINOX protocol, the planned Phase 3 start, regulatory milestone alternatives, sale-related costs and the distinction between June cash and pro forma resources. Original research revision date not stated; archive copy captured October 31, 2026.
$ETONResearch as of October 29, 2026PDF · 12 pages
Eton: specialty sales, acquisitions and cash conversion
The report examines HEMANGEOL and IMPAVIDO within Eton’s specialty-medicine portfolio and commercial infrastructure. It follows acquisition obligations, product economics, cash conversion and development milestones, setting revenue growth against the financing and execution needed to sustain it.
$DNTHResearch as of October 27, 2026PDF · 17 pages
Dianthus: complement inhibition, readouts and resources
This report explains claseprubart’s neuromuscular development program, the MMN safety-focused readout and the separate CIDP withdrawal evidence. It examines dosing schedules, trial populations, financial resources and dilution while keeping responder analyses distinct from randomized outcomes.
$FDMTResearch as of October 23, 2026PDF · 15 pages
4D Molecular Therapeutics: genetic medicines and clinical data
The report examines 4D Molecular Therapeutics’ engineered-vector platform, principal clinical programs and the clinical endpoints that matter for development decisions. It follows tolerability, durability, manufacturing and regulatory execution together with cash consumption, financing and dilution risks.
$CODXResearch as of October 29, 2026PDF · 19 pages
Co-Diagnostics: PCR authorization, installation economics and funding
Archived research separates point-of-care PCR development, environmental Vector Smart installations, Indian tuberculosis testing and Saudi manufacturing plans. It examines clinical and workflow evidence, FDA and CLIA review, the HPV study’s limited scope, recurring consumable demand, operating losses, loan funding and dilution.
$FULCResearch as of October 21, 2026PDF · 11 pages
Fulcrum: proposed transaction, distribution and residual value
This archive explains the proposed cash distribution and retained interest in a new migraine company, including the conditions that must precede closing. It assesses historical resources, development setbacks, transaction mechanics and the difference between announced per-share illustrations and a completed payment.
$GMABResearch as of October 29, 2026PDF · 16 pages
Genmab: late-stage oncology evidence, royalties and acquisition debt
The archived research compares LiGeR-HN1, RAINFOL-02 and EPCORE DLBCL-2 while preserving their different populations and endpoints. It examines Genmab’s royalty base, owned-product economics, AbbVie sharing obligations, Merus acquisition funding, June cash conversion and the financial demands of an expanding oncology business.
$KOSArchive captured October 31, 2026PDF · 15 pages
Kosmos: offshore production, GTA LNG, debt and retained equity value
Archived research examines Ghana fields, GTA LNG cargoes, U.S. Gulf development and the completed Equatorial Guinea divestiture. It connects production and commodity realizations with operating cash, investment needs, debt definitions, borrowing capacity, September note-redemption notices and the common shareholder’s residual claim. Original research revision date not stated; archive copy captured October 31, 2026.
$GRALResearch as of October 21, 2026PDF · 16 pages
GRAIL: cancer screening and galleri
The report examines Galleri’s multi-cancer screening proposition, the distinction between detection performance and patient benefit, and the clinical and regulatory evidence still required. It follows adoption, reimbursement, revenue quality, operating expenditure and the financial resources supporting the business.
$HResearch as of October 29, 2026PDF · 14 pages
Hyatt: hotel growth, distribution and capital returns
The archive examines Hyatt’s hotel-fee model, all-inclusive exposure and Distribution segment alongside the third-quarter outlook. It connects room openings, acquisitions and asset transactions with cash, debt and shareholder returns, explaining why operating growth and common-share value can diverge.
$PRZOArchive captured October 31, 2026PDF · 17 pages
ParaZero: net interception, customer integration and commercial funding
Archived research examines DefendAir Net Pods, physical counter-drone interception, vehicle-integration frameworks, early U.S. orders and the move toward recurring procurement. It separates non-binding cooperation from funded orders and recognized sales, and follows DropAir, gross margins, cash and deposits, conditional funding assumptions and share dilution. Original research revision date not stated; archive copy captured October 31, 2026.
$IDYAArchive captured October 31, 2026PDF · 17 pages
IDEAYA: darovasertib settings, DLL3 evidence and development funding
Archived research separates metastatic, neoadjuvant and adjuvant darovasertib programs and examines the evidence behind the wider precision-oncology pipeline. It covers IDE849 trial design and early data, synthetic-lethality programs, partner rights, June resources, rising research spending and equity compensation. Original research revision date not stated; archive copy captured October 31, 2026.
$INDVResearch as of October 29, 2026PDF · 15 pages
Indivior Pharmaceuticals: sublocade and supernus merger
The report examines SUBLOCADE’s commercial franchise and the proposed all-stock Supernus merger, separating corporate milestones from the different clinical study populations. It follows cash generation, liabilities, final transaction financing and the limits of extrapolating treatment-market opportunity to shareholder returns.
$SPROResearch as of October 20, 2026PDF · 18 pages
Spero: Utebzi economics, licensing and runway
The archive follows Utebzi from approval toward availability and examines the separate SP001 licensing arrangement. It explains royalties, partner obligations, cash resources and financing capacity, distinguishing management’s funding horizon from cash already received and future commercial execution.
$SYMArchive captured October 31, 2026PDF · 19 pages
Symbotic: warehouse robotics and backlog
The report examines Symbotic’s warehouse systems from architecture and deployment to customer economics and backlog conversion. It follows Walmart concentration, Exol, acquisitions, accounting comparability and the timing of customer payments, separating a large order book from cash generated for shareholders. Original research revision date not stated; this archive copy was captured October 31, 2026.
$STOKResearch as of October 29, 2026PDF · 15 pages
Stoke: Dravet evidence, EMPEROR design and the RNA funding path
Archived research examines zorevunersen’s RNA mechanism, early Dravet observations and the controlled EMPEROR study. It separates cognitive and seizure endpoints, Biogen rights, OSPREY optic-atrophy development, September financial updates, equity funding and the sequence from clinical results to a possible regulatory submission.
$IONQResearch as of October 27, 2026PDF · 17 pages
IonQ: quantum systems, bookings and financing
This report examines IonQ’s technical milestones, commercial contracts and acquisition strategy without treating bookings as recognized revenue. It connects quantum-computing and networking ambitions with operating losses, cash resources, financing and the execution required for larger deployments.
$KNSAResearch as of October 28, 2026PDF · 23 pages
Kiniksa: ARCALYST economics, event-driven studies and four share classes
The archived research follows ARCALYST adoption, collaboration obligations and the cash generated by the commercial franchise. It examines KPL-387 interval evidence, the event-driven PASTORALE design, KPL-1161 plans, supply and exclusivity risks, four-class ownership, voting rights and the distinction between listed float and total capital.
$SYREResearch as of October 19, 2026PDF · 23 pages
Spyre: SKYLINE evidence, dosing and capital structure
The report examines the three SKYLINE monotherapy programs and the limitations of open-label Part A evidence. It connects extended dosing ambitions, combination development and later readouts with cash use, financing instruments and the share-equivalent base behind the runway statement.
$TRAXResearch as of October 21, 2026PDF · 15 pages
First Tracks: celiac protection, mucosal repair and financing dilution
Archived research separates the controlled ANB033 gluten-challenge findings from the next mucosal-healing question and the broader CD122 development plan. It examines population and safety limits, EoE and earlier programs, the Anaptys separation, completed October financing, governance and the expanded shareholder denominator.
$TRDAResearch as of October 21, 2026PDF · 18 pages
Entrada Therapeutics: duchenne programs and delivery
The report examines Entrada’s intracellular-delivery platform, the first Duchenne patient cohort and the exposure, molecular and functional evidence needed from later doses. It follows the second DMD program and Vertex-partnered DM1 opportunity alongside cash, runway, ownership and the uncertainty of small exploratory datasets.
$KRROResearch as of October 27, 2026PDF · 16 pages
Korro Bio: rna editing and clinical evidence
The report examines Korro’s RNA-editing platform and the biological and clinical evidence needed to connect editing activity to patient benefit. It follows program milestones, delivery and safety questions, historical cash resources, operating consumption and the financing implications of development.
$KYMRResearch as of October 29, 2026PDF · 16 pages
Kymera: degrader evidence, pivotal plans and resources
The archive examines Kymera’s oral degrader programs, separating healthy-volunteer pharmacology from patient efficacy. It covers the KT-621 development pathway, KT-579 evidence, trial windows and September financial resources, together with spending and the risks behind management’s longer-term plans.
$TYRAResearch as of October 12, 2026PDF · 16 pages
Tyra: pediatric growth evidence and the funding base
This archive explains dabogratinib’s pediatric sentinel dataset, the larger BEACH301 study and the revised timing for initial results. It examines height-velocity limitations, competing oral therapy, the oncology program and financing, including common shares and pre-funded equivalents.
$LBRXArchive captured October 31, 2026PDF · 17 pages
LB Pharmaceuticals: NOVA evidence, tolerability and pivotal funding
Archived research examines LB-102 pharmacology, the randomized NOVA-1 dose comparisons and the limits of exploratory cognition findings. It separates measured weight changes from adverse-event summaries and follows NOVA-2, long-term safety development, June liquidity, July financing, employee equity and dilution. Original research revision date not stated; archive copy captured October 31, 2026.
$UALResearch as of October 28, 2026PDF · 16 pages
United Airlines: revenue quality, fleet renewal and financing pressure
Archived research examines premium demand, fuel recovery and the relationship between revenue growth and airline margins. It follows fleet delivery and capital commitments, MileagePlus economics, Starlink deployment, transborder competition review, September results and the cash needed after reinvestment and creditor claims.
$VRCAResearch as of October 22, 2026PDF · 14 pages
Verrica Pharmaceuticals: ycanth and clinical development
The report examines YCANTH’s commercial performance, the COVE-2 common-warts study and the separate VP-315 development program. It follows June liquidity, secured borrowing conditions and the difference between product dispensing, recognized revenue and cash available to fund further clinical work.
$LPCNResearch as of October 20, 2026PDF · 13 pages
Lipocine: bloom and endocrine programs
The report examines Lipocine’s endocrine and metabolic-development programs, formulation strategy and partnership economics. It distinguishes approved or licensed activities from investigational programs and follows clinical milestones, cash resources, operating expenditure and potential dilution.
$VTRSResearch as of October 24, 2026PDF · 15 pages
Viatris: portfolio rights, Pacira and financial obligations
The report examines Viatris’ pharmaceutical portfolio, product rights and the proposed Pacira acquisition alongside development milestones. It connects operating cash flow, debt, dividends and transaction funding with the distinction between an approval, a contractual territory right and a completed commercial contribution.
$MANEResearch as of October 20, 2026PDF · 15 pages
Veradermics: hair-growth evidence and the clinical pathway
The report examines Veradermics’ hair-growth studies and how endpoints, treatment duration and safety shape the development case. It connects the reported clinical observations with financial resources, competition and capital requirements, distinguishing an encouraging dataset from completed registration and commercial uptake.
$MEDPResearch as of October 26, 2026PDF · 15 pages
Medpace: award quality, backlog conversion and cash discipline
Archived analysis of the full-service clinical-research model and the path from net awards to recognized revenue and collected cash. It examines cancellations, sponsor funding, backlog rules, operating leverage, lease obligations, repurchases, leadership and the interpretation of book-to-bill alongside the dated quarterly accounts.
$VWAVResearch as of October 30, 2026PDF · 16 pages
VisionWave: conditional orders, terminated ventures and capital claims
Archived analysis distinguishes VisionWave’s acquired technology and operating subsidiary from defense systems still in development. It examines the unwound Sadot venture, conditional C.M. acquisition, VARAN customer requirements, intangible assets, debt and equity facilities, going-concern exposure and the proposed shareholder authorizations.
$WBTNResearch as of October 20, 2026PDF · 18 pages
WEBTOON Entertainment: digital comics and disney
The report examines regional digital-comics demand, paying users, the Disney platform initiative and the economics of adaptations and games. It follows NAVER control, capital commitments, thin margins and the IPO-litigation process, keeping commercial launch dates separate from financial and legal outcomes.
$WORXResearch as of October 27, 2026PDF · 18 pages
SCWorx: data operations, Nasdaq and financing
The archive examines SCWorx’s healthcare-data business and the economics of new software workflows. It sets revenue, losses and liquidity against Nasdaq monitoring, warrant exercises and resale registration, explaining dilution and the limits of interpreting registration capacity as company cash.
$MNDRResearch as of October 30, 2026PDF · 15 pages
Mobile-health Network Solutions: digital healthcare and infrastructure
The report separates the established digital-healthcare activities from clinic software, Ghana plans and proposed Malaysian data-center development. It follows conditional funding, staged commitments, regulatory history and share structure, preserving the annual financial update alongside the older interim discussion.
$XBIOResearch as of October 15, 2026PDF · 14 pages
Xenetic: DNase translational evidence and Santersus ownership mechanics
Archived research examines the DNase and neutrophil-extracellular-trap hypothesis, CAR T translational work and the first small investigator-initiated lymphoma study. It separates Santersus NucleoCapture programs from Xenetic’s current assets and traces transaction conditions, illustrative issuance, royalty support, standalone cash and related-party risks.
$YPFResearch as of October 29, 2026PDF · 20 pages
YPF Sociedad Anónima: vaca muerta and lng
The report examines Vaca Muerta production, oil-export routes and the staged LNG development opportunity within YPF’s integrated business. It follows commodity assumptions, investment, debt, currency and Argentine political risk, preserving detailed June analysis and the later key financial update.
$MRVLResearch as of October 28, 2026PDF · 17 pages
Marvell: data-center systems, earnings and cash
This archive follows Marvell’s custom silicon, optical connectivity and data-center infrastructure products through the deployment cycle. It examines earnings quality, customer concentration, working capital and capital allocation, separating technology demonstrations and product launches from recognized revenue and collected cash.
$MYGNResearch as of October 30, 2026PDF · 18 pages
Myriad Genetics: prenatal divestiture, retained tests and revenue quality
The archived report examines the proposed Labcorp prenatal-business sale and the economics of Myriad’s retained diagnostics portfolio. It covers reimbursement estimates, test-volume conversion, Precise MRD and PrGIS evidence, debt and asset-sale provisions, June cash use, share dilution and the execution required for a durable turnaround.
$ZBIOResearch as of October 30, 2026PDF · 16 pages
Zenas: obexelimab review, portfolio and funding
This report follows obexelimab’s regulatory review and the separate lupus and multiple-sclerosis development opportunities. It assesses clinical designs, licensing and acquisition economics, debt and royalties alongside reported cash, emphasizing that each program has its own evidence and financing requirements.
$OCSResearch as of October 29, 2026PDF · 19 pages
Oculis Holding: eye-disease pipeline and clinical data
The report examines Oculis’ ophthalmology pipeline, the different study populations and the evidence required for each regulatory path. It follows efficacy, safety, trial design and development milestones alongside Swiss-franc financial statements, U.S. trading observations and potential financing dilution.
$PCVXResearch as of October 12, 2026PDF · 15 pages
Vaxcyte: VAX-31, OPUS evidence and financing
The report explains the VAX-31 adult and infant programs, serotype-level comparisons and the limits of topline vaccine evidence. It assesses the OPUS development calendar, competitive context, cash and investments, equity financing and convertible obligations without treating immunogenicity as an approval.
$PHVSArchive captured October 31, 2026PDF · 14 pages
Pharvaris: response endpoints, prevention evidence and separate filings
Archived research distinguishes RAPIDe-3 on-demand response times from CHAPTER-3 prevention endpoints and the acquired-angioedema CREAATE program. It examines safety, longer-term exposure, regulatory sequencing, commercial differentiation, euro cash consumption, equity financing and the gap between pivotal evidence and an approved business. Original research revision date not stated; archive copy captured October 31, 2026.
$PRMEResearch as of October 28, 2026PDF · 13 pages
Prime Medicine: prime editing and liver programs
The report examines prime editing, the liver-development strategy and the separate PM359 regulatory evidence. It distinguishes preliminary clinical observations, company plans and draft regulatory guidance, then follows cash consumption, financing needs and the time available to reach the next data.
$PTGXResearch as of October 27, 2026PDF · 13 pages
Protagonist: partnered medicines and recurring royalties
The archive examines the approved partnered programs and the distinction between milestone income and recurring royalties. It connects clinical evidence, partner economics, internal peptide development, cash use and repurchases with the financial disclosures needed to establish a durable earnings base.
$SCTXResearch as of October 2, 2026PDF · 19 pages
Scribe: epigenetic silencing, first-human evidence and IPO economics
The archived report examines STX-1150’s PCSK9 silencing approach and distinguishes the first-human study from preclinical cardiovascular evidence. It follows the STX-1200 and STX-1400 pipeline, CIRM support, partner rights, July IPO and note conversion, pro forma liquidity, lock-up timing and the evidence required for durable LDL-C lowering.
$SGMTResearch as of October 22, 2026PDF · 15 pages
Sagimet Biosciences: denifanstat and aurora
The report examines FASN inhibition in acne, the partner studies in China and the design and clinical questions facing the U.S. AURORA program. It follows adolescent development, tolerability, retained rights and the distinction between June financial resources, October financing and later runway guidance.
$SLNResearch as of October 24, 2026PDF · 12 pages
Silence: divesiran evidence and the next development stage
This report explains the SANRECO Phase 2 results and the remaining steps toward a later divesiran study. It examines clinical endpoints, enrollment, cash and the August financing alongside ADS mechanics, dilution and the difference between a successful readout and commercial value.
$SPAIResearch as of October 29, 2026PDF · 15 pages
Safe Pro: threat-detection deployment, procurement and cash conversion
Archived analysis of Ground Truth computer vision, deployment settings and the limits of field-detection claims. It follows government and humanitarian subcontracting, customer concentration, preliminary revenue, receivable collection, June cash use, dilution and the financial requirements for repeat commercial delivery.
$SPIRResearch as of October 20, 2026PDF · 15 pages
Spire Global: weather data and cash conversion
The report examines satellite-derived weather data, defense demand and the contractual steps between awards, service delivery and collected cash. It follows NOAA and EUMETSAT commitments, manufacturing execution, customer development, operating losses and the financial resources available for the wider business.
$GRVYResearch as of July 14, 2026PDF · 7 pages
Gravity: the Ragnarok franchise, cash discount and GungHo control
The July 14, 2026 research examines the Ragnarok regional-launch model, Q1 2026 and FY2025 financial results, the historical cash-and-instruments position and GungHo’s voting control. It compares the cash-discount thesis with franchise concentration, uneven margins, limited liquidity and the then-pending first interim dividend, using constructive and pressure scenarios. Later dividend decisions and financial updates are covered in the live stock hub.
$ATLXResearch as of July 2, 2026PDF · 9 pages
Atlas Lithium: Neves project economics, offtake and funding risk
A dated study of the Neves lithium project in Brazil: feasibility economics, plant delivery, permitting and offtake relationships with Mitsui, Chengxin and Yahua. It examines the original March balance sheet, convertible debt, share dilution, voting control and the Atlas Critical Minerals structure. Bull, bear and execution scenarios show how financing needs and the lithium cycle can affect the project; later company developments are covered in the live hub.
$NNEResearch as of July 1, 2026PDF · 8 pages
NANO Nuclear Energy: microreactor designs, fuel logistics and the capital runway
The July 1 research examines KRONOS, LOKI, ZEUS and ODIN alongside the strategy to integrate HALEU fuel logistics and secured nuclear-material transport. It preserves the March 2026 balance sheet, equity-financing and dilution discussion, regulatory and testing milestones, competition, governance, and constructive and cautious scenarios. Later financial reports, project agreements and regulatory developments are covered in the live hub.
Disclaimer. The reports in this library are published by Merlintrader for educational and informational purposes only. They are independent journalism and research, dated to the day printed on each report. They do not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and they are not research reports within the meaning of applicable United States securities regulation.
Figures come from public filings, company releases, official trial registries and regulatory documents, stated with their reference dates. They become outdated as new filings and events occur: verify every figure against the primary source and the current stock hub before relying on it. Small and mid-cap and biotechnology stocks can be extremely volatile and may result in partial or total loss of capital. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Reports are for personal use only. Redistribution is prohibited. Full legal information is available on the disclaimer and terms of use and privacy pages.
